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ABSTRACT 
Members of tiie lentivirus subfamily of retroviruses are characterized as causing slow, 
chronic disease. Atypical of other lentiviruses, such as human immunodeficiency virus type 
1, equine infectious anemia virus (EIAV) may produce a rapid, variable disease course in 
horses. Infected horses may undergo an acute episode of disease involving viremia, fever, 
and thrombocytopenia. Following this acute period, horses may resolve to an inapparent 
infection or suffer numerous recurrent cycles of viremia, fever, and thrombocytopenia. 
Horses which survive clinical episodes usually become inapparent carriers of the virus for 
life. Numerous virus and host factors contribute to the phenotj^ic manifestations of disease. 
These include, but are not limited to, the rate of virus replication, the host immune response, 
and genetic variation of the virus. Genetic variation in EIAV has been identified in a region 
overlapped by the genes encoding the transmembrane protein and the fran^-regulatory 
protein Rev. Rev is a nucleocytoplasmic transport protein which regulates the expression of 
viral structural proteins and progeny RNA molecules during the late phase of virus 
replication. Therefore, factors which modulate Rev activity may result in changes in virus 
replication and ultimately contribute to virus pathogenesis in vivo. The long term goal of this 
research project is to determine the contribution of Rev variation to the manifestation of 
clinical disease during EIAV infection. To accomplish this goal, we first demonstrated that 
genetic variation modulates Rev activity in vitro. We then characterized variation within Rev 
in an experimentally-infected pony. Functional analysis of the dominant Rev variants at 
various time points during infection indicated that the variants dominant during the clinical 
periods possessed more nuclear export activity than those dominant in the acute or aclinical 
periods. To fiuther understand the significance of Rev variation, we have mapped the cis-
and trans-diCXing elements required for the nuclear export and alternative splicing activities of 
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Rev. Specifically, we mapped the alternative splicing domain of Rev and identified the RRE 
of EIAV. These studies provide strong evidence that variation in Rev is an important 
determinant of virus replication and therefore a significant factor of EIAV pathogenesis. 
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CHAPTER 1. GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation describes a genetic and molecular characterization of the Rev 
protein of equine infectious anemia virus (EIAV). The genetic component describes the 
biological significance of variation in Rev both in vitro and in vivo. There is also a molecular 
examination of Rev function, with an emphasis on the mechanism by which Rev mediates 
alternative splicing during virus replication. The dissertation is in the alternative format and 
is divided into six chapters, four of which are presented as manuscripts. Chapter 1 is a 
general introduction to EIAV as well as a background of the molecular biology of the Rev 
family of proteins, with a specific emphasis on EIAV Rev. The introduction provides general 
information to enable the reader to understand the following chapters and to justify the 
significance of the research. Chapter 2 describes the finding that amino acid variation in Rev 
alters biological activity. This chapter was published in the Journal of Virology as a short 
form article. This work was done in collaboration with the laboratory of Thomas J. Hope, 
which provided the pERRE-All, pERRE-1, and pERRE-2 plasmids. All of the work in this 
manuscript was performed by myself except the sequence data in Fig. 2. Data from this 
chapter lays the groundwork for the studies presented in the following chapter. Chapter 3 
presents rev sequence data from EIAV recovered from an experimentally-infected pony and 
demonstrates that variation in Rev may be an important factor contributing to clinical 
disease. This work was done in collaboration with Prasith Baccam and J. Lindsay Oaks. 
Prasith Baccam performed the sequencing and genetic analysis of the rev clones and J. 
Lindsay Oaks performed the experimental infection, provided the clinical data and serum 
samples, and performed the semi-quantitative RT-PCR for detection of virus load. This 
chapter has been organized into a manuscript for submission to the Journal of Virology. 
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Chapter 4 details a molecular characterization of Rev-mediated altemative splicing. This 
work was done in collaboration with the laboratory of C. Martin Stoltzfiis, which performed 
all the in vitro splicing assays. The work in this chapter has been organized into a paper that 
has been submitted to the journal Molecular and Cellular Biology. The data in this chapter 
presents the finding that Rev binding to an RNA element in EIAV exon 3 mediates both 
nuclear export of incompletely spliced viral mRNAs and exon 3 altemative splicing. Chapter 
5 presents domain mapping studies of Rev by deletion analysis. The data in this chapter 
identifies domains of Rev required for activity and maps a region of the protein required for 
altemative splicing. This chapter wUl be combined with other work from the Carpenter lab 
and submitted in the future to the journal Virology. Following chapter 5 is a general 
conclusion of these studies and their impUcation for studies of EIAV and retroviruses in 
general. Within the conclusion, I also present my recommendations for future research on 
EIAV Rev. 
Introduction 
Equine infectious anemia virus (EIAV) is the etiological agent of a persistent, life­
long, variable disease in members of the family Equidae. The cUnical signs of disease 
include, but are not limited to: Anemia, fever, thrombocytopenia, and weight loss (reviewed 
in 20). EIAV is a member of the Lentiviridae subfamily of the virus family Retroviridae. 
Other members of this family include the human, simian, and feline immunodeficiency 
vimses (HtV-l and -2, SIV, and FTV, respectively), bovine immunodeficiency virus (BIV), 
caprine arthritis encephalitis virus (CAEV), and visna virus. EIAV is mechanically 
transmitted from host to host via interrupted feeding of hematophagous arthropods (e.g. 
common horse flies) or artificially by instruments containing contaminated blood products. 
Development of a practical diagnostic test, the agar gel immunodifftision (AGID) test, and 
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subsequent eradication measures have lowered the disease prevalence to < 5% in the United 
States of America. However, the genetic and biological similarities of the virus to other 
members of the Lentiviridae and the dynamics and pathology of the variable disease course 
have shown EIAV to be an important tool for comparative virology, cell biology, and 
pathology. 
Clinical disease 
EIAV infects cells of the macrophage/monocyte lineage (8, 37). It is now clear that 
the virus replicates predominantly in differentiated monocytes, especially tissue macrophages 
(8). Undifferentiated monocytes appear to be susceptible to viral infection, but do not 
produce infectious virions. The state of monocyte differentiation also appears to be an 
important determinant of virus replication. Early differentiating monocytes produce low 
levels of virus whereas the highest levels of replication are seen in the tissue macrophages of 
the spleen and liver. In rare cases, EIAV has been found to replicate in other tissues such as 
the lung, brain, muscle, and kidney. Virus transport throughout the host is believed to be 
facilitated by infectious immune complexes (7). Immune complexes are normally cleared 
from sera by macrophages in the liver (Kupffer cells) and spleen. These cells represent 
highly susceptible targets of EIAV infection. 
Infection of horses with EIAV can result in an acute febrile illness within one to two 
weeks, followed by a period of recurring cycles of fever and thrombocytopenia, possibly 
accompanied by anemia and weight-loss. Each clinical episode is associated with high levels 
of virus replication and the emergence of new antigenic variants of virus (20, 27). The 
frequency of the cycles declines over time, with the majority occurring within the first year 
postinfection. Horses which survive the early clinical episodes typically become clinically 
inapparent, seropositive carriers of the virus for life. Thus, the majority of EIAV-infected 
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horses are healthy, inapparent carriers. Despite the virus' name, anemia is not a typical sign 
of infection. The mechanism of anemia has been attributed to both immune-mediated 
clearance of complement-coated erythrocytes and general bone marrow suppression (47). 
To date, there is a number of conflicting reports concerning the mechanism of EIAV-
induced thrombocytopenia. Thrombocytopenia associated with HTV-l infection has been 
attributed to an increase of platelet-associated antibody, abnormalities in megakaryocyte 
(MK) development and subsequent platelet production, and a general decrease in platelet 
survival (55). However, EIAV does not infect MKs and no depletion of MKs is associated 
with EIA disease (7,45, 52). Indeed, one study observed an increase in the number of MK 
cells in the bone marrow of infected ponies, accompanied by an enlargement in the overall 
area and nuclear size of MKs (45). Platelet-associated IgM and IgG have been observed to 
increase with EIAV infection (7). Therefore, it has also been proposed that thrombocytopenia 
may result from clearance of EIAV-platelet immune complexes in sera. However, another 
study demonstrated that severe combined immunodeficiency (SCDD) foals infected with 
EIAV still developed thrombocytopenia, suggesting that the loss of platelets is not the result 
of an immune-mediated mechanism (52). Furthermore, histological examination of the bone 
marrow of the infected SCED foals also failed to show any change in MK numbers or 
morphology suggesting that immune mediated destruction of MKs does not occur (52). 
Studies examining platelet production and function have also been conflicting. Whereas one 
study observed a suppression of platelet production by an unknown mechanism (52), another 
study indicated platelet production was not compromised (45). The latter authors also 
showed platelets isolated from EIAV infected ponies had decreased aggregation responses in 
vitro. Therefore, they suggested that increased activation of platelets in vivo resulted in 
quicker removal of platelets from circulation (45). 
5 
Virus structure 
Retroviruses are single-stranded, positive-sense RNA viruses which possess the 
ability to synthesize dsDNA from ssRNA using a RNA-dependent, DNA polymerase, or 
reverse transcriptase (RT), encoded within the pol gene of the virus. Other proteins encoded 
by the pol gene include the viral integrase, a dUTPase, and a protease. The relatively small 
genome of EIAV (approximately 8.3 kb) also contains other features common to aU 
retroviruses including gag and env structural genes and flanking long terminal repeats 
(LTRs) (Fig. 1). The gag genes products comprise the irmer structural proteins of the virion 
including the nucleocapsid, capsid, and matrix proteins. The env gene encodes a polyprotein 
that is proteolytically cleaved by cellular factors into the transmembrane (TM) and surface 
(SU) glycoproteins of the virion. Both the TM and SU play important roles in virus entry. 
The SU contains the key determinants for binding of the cell specific receptor(s), and the TM 
facilitates fusion of the virus with the host cell membrane. 
I 
LTR pol IMI gp90 gp-a-s |ltr 
cjag EB 
gag, pol 
env 
tat, rev 
FIG. I. Splicing patterns of EIAV. Structural proteins (Gag, Env) and viral enzymes (Pol) are 
translated from the unspliced and singly-spliced mRNAs. Both Tat and Rev are expressed 
from the triply-spliced, four exon mRNA. In the presence of Rev, a new multiply-spliced 
mRNA appears in which exon 3 is skipped, producing a three exon species that codes for 
only Tat. Expression of the two exon mRNA is also dependent upon the presence of Rev. 
This mRNA codes for Ttm, a protein of unknown function (3). 
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Virus particles contain a core structure comprised of two copies of the ssRNA viral 
genome associated with the nucleocapsid protein, integrase, dUTPase, and reverse 
transcriptase. The RNA-protein complex is surrounded by the 26 kDa capsid protein. 
Encompassing the capsid is the matrix layer which couples the protein core of the virus with 
the surrounding membrane. The envelope of the virus is acquired from the host cell 
membrane during the budding process. The 45 kDa TM protein is embedded in the 
membrane, and the 90 kDa SU protein is superficially associated with TM on the outside of 
the membrane. Several other non-structural, regulatory proteins are also encoded in the EIAV 
genome including Tat, Rev, and Ttm. These will be discussed in detail in the replication 
section. The LTRs flanking either side of the viral genome possess several factors important 
for viral repUcation. Included in the LTR is the transcription start site and the viral gene 
promoter containing numerous transcription factor binding sites including PU.l, Oct, and 
CREB motifs (32). The LTR also contains cw-acting sequences necessary for reverse 
transcription of viral RNA and dsDNA integration into the host cell genome. 
Replication/gene expression 
The virus life cycle begins with attachment to the host cell. Attachment is mediated 
through interactions between the surface envelope protein and one or more cellular receptors. 
The cellular protein(s) required for EIAV attachment and internalization have not been 
delineated. However, as mentioned above, EIAV is thought to enter host cells by a fusion 
mechanism common to other retroviruses. Upon entrance into the cell, the capsid core of the 
virion disassembles and reverse transcriptase converts the viral ssRNA to circular dsDNA. 
Upon completion of reverse transcription, a pre-integration complex forms containing the 
viral dsDNA associated with the integrase and matrix proteins. The complex migrates into 
the nucleus and the dsDNA integrates randomly into the host cell genome. Once the DNA is 
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inserted, transcription initiates, promoted by cellular transcription factors and RNA 
polymerase n. 
Since all gene transcription initiates at a single site in the LTR, EIAV uses several 
mechanisms to differentially express genes, including ribosomal frameshifting, production of 
polyprotein precursors, and alternative splicing. As a complex retrovirus, EIAV possesses 
two stages of gene expression: An early, non-structural regulatory phase, and a late, 
structural phase. The two phases are differentiated by the patterns of viral mRNAs expressed 
in the cell. Initial gene expression is characterized by a fuUy spliced, bicistronic mRNA 
which gives rise to da^o regulatory proteins. Tat and Rev (6, 50) (Fig. 1). Tat is a viral 
transcriptional activator which binds a secondary structure near the transcriptional initiation 
site in the newly synthesized viral mRNA (called the TAR element) and increases the 
efficiency of transcription (12). The regulatory protein Rev regulates expression of the late 
class of viral mRNAs. These RNAs are incompletely spliced, code for the viral enzymes and 
structural proteins, and act as progeny RNA molecules. Hence, Rev is absolutely required for 
virus replication. In the presence of Rev, two alternatively spliced mRNAs also appear- a 
three exon species encoding Tat and a two exon mRNA encoding Ttm, a 27 kDa protein of 
unknown function (3) (Fig. 1). This Rev-mediated alternative splicing phenomenon is unique 
among retroviruses and will be discussed in a later section. 
During the late phase of virus replication, the viral core proteins assemble in the 
cytoplasm of the cell and viral envelope proteins are processed and transported to the 
membrane of the host cell. Assembly occurs at the host cell membrane, and virions bud from 
the cell in a non-lytic fashion. Packaging of the pol gene products occurs as large Gag-Pol 
poljrprotein precursors because the individual enzymes lack motifs necessary for 
incorporation into the virion. Cleavage of the polj^rotein precursor occurs after the virus is 
in the cell-free state. Studies of protease deficient viruses have demonstrated that virions with 
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intact Gag-Pol polyproteins are unable to infect host cells. Hence, until proteolytic cleavage 
has occurred, virus particles are considered "immature." 
Rev-mediated nuclear export 
The simplest retroviruses, such as murine leukemia virus, regulate altemative splicing 
by using suboptimal splice sites. Therefore, numerous mRNAs are produced from the same 
pre-mRNA at a fixed rate, allowing for production of ail proteins/RNAs necessary for viral 
replication. Complex retroviruses, such as EIAV and HTV-l, utilize Rev-like pathways to 
differentially express incompletely-spliced mRNAs coding for virion structural and 
enzymatic proteins and progeny EINA molecules (reviewed in 11). The mechanism of action 
of the prototype member of this family, HTV-l Rev, has been well characterized. HTV-l Rev, 
a nuclear shuttling protein, facilitates export of incompletely spliced RNAs by interacting 
with the viral pre-mRNA and exporting it before complete splicing can occur. HTV-l Rev 
interacts with the pre-mRNA at a specific sequence called the Rev-responsive element (RRE) 
(53). The HTV-l RRE is a complex multi-stem-loop structure located near the SU-TM 
cleavage site (9, 10, 29). After a single Rev protein binds the RRE, additional Rev proteins 
multimerize (38) forming a nuclear export signal that interacts with the CRMl nucleoporin 
pathway to transport incompletely spliced RNAs from the nucleus (4, 13, 49, 51). This non-
mRNA pathway is normally important in the nuclear export of U small nuclear RNAs 
(snRNAs) (13, 49). Rev export pathways have been identified in many retroviruses including 
FTV, BTV, visna virus, CAEV, bovine leukemia virus (BLV), and human T-cell leukemia 
virus (HTLV) (11). Functional homology exists between all Rev-like proteins although they 
typically share little sequence similarity. The most conserved region among these proteins is 
the leucine rich nuclear export signal (NES), important for recognition of the CRMl 
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pathway. Indeed, in several cases, the NES of different Rev-like proteins have been shown to 
be interchangeable (14, 30). 
EIAV Rev is functionally homologous to HTV-l Rev, but remains less well 
characterized. EIAV Rev is a highly charged, 165 amino acid protein translated from exons 3 
and 4 of a multiply spliced, four exon, bicistronic mRNA which also encodes Tat (6, 35). The 
amino acid sequence of the MA-1 strain Rev bears little homology to any other Rev-like 
proteins (Fig. 2). The NES of Rev has been mapped to amino acids 31-55 (14), and domain 
swapping experiments have shown it to be interchangable with the Rev proteins of HTV-l 
and visna virus. A recent report has proposed that the nuclear localization signal of Rev is in 
the arginine rich C-terminus of the protein (17). The EINA binding, multimerization, and 
alternative splicing domains of EIAV Rev have not been identified. 
Wmf^ KFARnOEMNT ,KEESKEEKRRMMAKIDP(^ Pr-iRS(XM:K\7LR 
QSLEEEEIESQTCIAEa^HLGPGPIQHIPSRRI^WIKGQirjQAEVLQ 
EElLEMmiGVQQVSKEIX3EVIRGIWE?ELYBKEnDQK!3DFSJ«AiGGY'QR 
AaERUAGBQSSPRVIiE^HSDSKE^RKKHL 
Figure 2. Amino acid sequence of the Rev protein of the MA-1 strain of equine infectious 
anemia virus. Location of the nuclear export signal (NES) is underhned. 
Rev-mediated alternative splicing 
Pre-mRNA splicing is a complex process which occurs in a large RNA-protein 
complex called the spUceosome. Numerous protein factors associate with the snRNAs Ul, 
U2, U4, U5, U6, and the pre-mRNA substrate which results in removal of each intron via two 
rra/z^-esterification reactions (reviewed in (34, 48)). Assembly of the snRNAs and protein 
factors is a highly ordered process which requires precise recognition of sphce site and 
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branch point sequences. The presence of suboptimal recognition sequences can result in the 
inefficient splicing of certain exons, or alternative splicing. Use of suboptimal splice sites is 
mediated in part by cij-acting RNA sequences that either enhance or repress recognition of a 
splice site by the spliceosome. Exon splicing enhancers (ESEs) and silencers (ESSs) have 
been described for many virus and cellular RNAs (2). ESEs are typically purine rich 
sequences embedded within alternatively spliced exons. The purine rich sequences mediate 
exon recognition through interactions with members of the SR protein family of spUcing 
factors. SR proteins are both essential splicing factors and regulators of alternative splicing 
(reviewed in 15). As essential splicing factors, SR proteins are required for early steps of 
spliceosome assembly (44). SR proteins regulate alternative splicing by binding ESEs and 
recruiting essential splicing factors to suboptimal splice sites near ESE sequences resulting in 
inclusion of alternatively splice exons. The effect of SR proteins on alternative splicing has 
been shown to be dose dependent, further suggesting SR proteins are important regulators of 
alternatively spliced mRNAs. 
All retroviruses utilize altemative splicing to differentially express multiple genes 
from a single pre-mRNA. The complex retroviruses mediate expression of incompletely 
spliced mRNAs via Rev export pathways. In addition to promoting nuclear export of 
incompletely spliced RNA, EIAV Rev also regulates exclusion of exon 3 of the multiply 
spliced RNA (Fig. 1) (31). In the presence of Rev, a new multiply-spliced mRNA, lacking 
exon 3, is produced. Exon 3 is flanked by a suboptimal splice acceptor and contains a purine 
rich, ESE-like sequence which has been shown to interact with the SR protein ASF/SF2 in 
vitro (16). This suggests that recognition of exon 3 may require SR protein-ESE interactions, 
and furthermore, that Rev mediated skipping of exon 3 may result from a disruption of such 
interactions. 
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Viral persistence 
Viral pathogenesis and persistence over a life-long infection is dependent upon both 
host and viral factors. Genetic variation is one of the important mechanisms by which 
retroviruses persist. Variation in retrovimses results from errors produced during reverse 
transcription (19, 23, 36, 39). The reverse transcriptase enzyme is a low fidelity RNA-
dependent, DNA polymerase. The continual misincorporation of nucleotides allows for rapid 
virus evolution in the constantly changing host environment. Typically, variation is scattered 
throughout the retrovirus genome. However, variation in EIAV is localized to three principle 
regions: The virus long terminal repeat (LTR), the SU protein (gp90), and a region 
overlapped by the TM protein (gp45) and the major exon of rev (1,5, 32). 
Genetic variation in structural proteins is a weU-studied mechanism of EIAV 
persistence. The largest degree of variation and emergence of new antigenic variants occurs 
during periods of high viremia (20, 27). Antigenic variation has been accepted for a long 
time as an important mechanism of persistence. Variation of the surface envelope and 
transmembrane proteins can occur as point mutations, insertions, or dupUcations. These 
changes can alter antigenicity and allow evasion of host immune responses throughout 
infection (21, 25-27, 33, 40-43, 46, 54). Variation in the SU protein is recognized as one of 
the principle mechanisms of evasion of the immune response. Typically, the largest variation 
in SU occurs within the principal neutralization domain and a defined hypervariable region. 
Recent studies in other retroviruses suggest that genetic variation in the virus LTR 
and other regulatory proteins may contribute significantly to persistence (5, 28, 32). Genetic 
variation which decreases the replication competence of a virus may play a role in evasion of 
the host immune response by down-regulating production of immunodominant stmctural 
proteins. The virus LTR is required for viral integration into the host chromosome and 
contains the promoter region and the only transcription start site for the virus. In vivo studies 
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have shown that nucleotide sequence changes in the EIAV LTR alter transcription factor 
binding sites (32). Altering, adding, or removing transcription factor binding sites might 
modulate overall levels of viral transcription and facilitate gene expression in cells other than 
differentiated monocytes. Hence, changes in transcription factor binding sites may modulate 
levels of virus gene expression during the course of infection and/or shift cell tropism (32). 
Variation in the regulatory genes of complex retroviruses may provide yet another 
mechanism by which retroviruses persist. Variation in the EDTV-l rev, and another accessory 
gene, nef, has been correlated with attenuated viruses in long term non-progressor patients 
(LTNPs, patients who do not develop AIDS within ten years) (18, 22, 24). Variation in Rev 
may alter levels of virus replication by modulating the production of the late structural 
proteins which may act as a mechanism to evade the host immune response. This hypothesis 
is supported by the identification of Rev-attenuated phenotypes in asymptomatic HTV-l 
infections and in LTNPs (22). Genetic variation in EIAV Rev may also be an important 
factor of disease pathogenesis. Extensive nucleotide substitutions have been found in the 
EIAV rev ORF both in vivo and in vitro (I, 28). Variation in EIAV Rev may modulate the 
production of virus structural proteins and hence, virus replication in vivo. Furthermore, Rev 
attenuation may be an important factor for long-term virus persistence in subclinical EIAV 
infections. 
Overall goal 
Rev post-transcriptionally regulates expression of incompletely spliced mRNAs 
coding for virus stmctural proteins and providing for progeny RNA molecules. Therefore, 
Rev is absolutely required for virus replication and factors which modulate Rev activity may 
result in changes in virus replication, and ultimately, disease pathogenesis in vivo. The long-
term goal of this research is to determine if variation in EIAV Rev contributes to viral 
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pathogenecity during clinical disease. This does not, however, imply that variation in Rev is 
the sole or dominant regulator of virus replication in vivo. The importance of variation in the 
LTR and the SU protein has been well studied and recognized. Instead, we propose that 
variation in Rev may be an additional factor contributing to EIA pathogenesis. To achieve 
this goal, we proposed to accomplish the following: 
1. Determine if variation in rev alters nuclear export activity. (Chapter 2) 
2. Analyze rev variation in an experimentally infected animal to determine if 
variation correlates with clinical disease. (Chapter 3) 
To fully grasp the significance of variation in rev, we must further understand the 
mechanism of Rev function. EIAV Rev has been shown to be functionally homologous to 
HTV-I Rev. The HTV-l Rev export pathway has been well characterized and therefore serves 
as a good model for EIAV Rev function. However, EIAV Rev shares little sequence 
homology with HTV-l Rev, and at the beginning of these studies, only the NES of EIAV Rev 
had been mapped. Therefore, an additional goal of this research was to delineate the cis- and 
trans-acimg factors necessary for Rev function. Specifically, we proposed to do the 
following: 
1. Identify the EIAV Rev responsive element. (Chapters 2 and 4) 
2. Delineate the mechanism of Rev-mediated alternative splicing. (Chapters 4 and 5) 
3. Map the domains of Rev required for RNA nuclear export. (Chapter 5) 
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CHAPTER 2. BIOLOGICAL CHARACTERIZATION OF REV VARIATION IN 
EQUINE INFECTIOUS ANEMIA VIRUS 
A paper published in Journal of Virology 
Michael Belshan', Matthew E. Harris^, Anne E. Shoemaker', Thomas J. Hope\ 
and Susan Carpenter' 
ABSTRACT 
Sequence analysis identified significant variation in the second exon of equine infectious 
anemia virus (EIAV) rev . Functional analysis indicated that limited amino acid variation in Rev 
significantly altered the export activity of the protein, but did not affect Rev-dependent 
alternative splicing. EIAV Rev can mediate export through two independent cis-acting Rev 
responsive elements, and differences among Rev variants were more pronounced when both 
RREs were present. Variation in Rev may be an important mechanism for regulation of virus 
replication in vivo and contribute to changes in clinical disease. 
INTRODUCTION, RESULTS, AND DISCUSSION 
Equine infectious anemia virus (EIAV) is a member of the lentivirus subfamily of 
retroviruses and possesses many of the characteristic features of that subfamily including a 
complex genome organization, tropism for cells of the monocyte/macrophage lineage, and 
establishment of a persistent, lifelong infection. Whereas lentivirus infections are typically 
characterized by a slow, chronic disease, EIAV can induce a rapid, variable disease course in 
horses. Horses which survive early clinical episodes carry a lifelong, persistent infection with 
low viral load. The rapid changes between clinical stages of disease which occur during EIAV 
infection provide for an excellent model for analyzing factors which contribute to lentivirus 
pathogenesis and persistence. One factor important in EIAV persistence and pathogenesis is 
genetic and antigenic variation. Genetic mutations in the viral env gene are associated with the 
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occurrence of antigenic variant viruses, and the role of antigenic variation in EIAV persistence 
has been extensively studied (14, 20,29, 32, 35). Additional clusters of genetic variation are 
found in the virus long terminal repeat (LTR) and in the region of gp45/Rev overlap (1,4, 21, 
27). The biological significance of variation in these regions is not clear, however, genetic 
changes which alter levels of viral gene expression may be important factors in viral pathogeneis 
in vivo. EIAV replicates in cells of the monocyte/macrophage lineage (28) and the severity of 
clinical and pathological signs of disease is closely associated with levels of viral replication in 
these cells (3). Therefore, variation in viral regulatory elements may modulate overall levels of 
virus replication and contribute to changes in clinical disease course. 
Lentiviruses utilize complex mechanisms to regulate virus replication. The regulatory 
protein Rev fianctions to direct the nuclear export of incompletely spliced viral RNAs encoding 
viral stmctural proteins during the late phase of virus replication. Rev-dependent RNA export 
pathways have been described for numerous lentiviruses (reviewed in 9), and the HTV-l Rev-
mediated RNA export pathway is the best characterized. HIV-1 Rev binds a secondary structure 
in the viral pre-mRNA called the Rev Responsive Element (RRE) (8,24,42), multimerizes (22, 
23, 34,41), then utilizes a non-mRNA nuclear export pathway to redirect movement of 
incompletely spliced RNA from the nucleus (2, 10, 11,40). Discrete functional domains within 
the protein mediate the interactions of Rev with cellular proteins and viral RNA required for 
nuclear localization, RNA binding, multimerization and nuclear export. 
EIAV Rev is a 165 amino acid protein translated from a bicistronic four exon mRNA 
coding for botii Tat and Rev (7, 39). The nuclear export signal (NES) of EIAV Rev has been 
mapped to amino acids 31-55 (12), and domain swapping experiments have shown that the 
EIAV Rev NES can substitute for the HTV-l or visna virus NES (2, 25, 30). Other functional 
domains of EIAV Rev have not yet been identified. EIAV Rev also has an additional, apparentiy 
unique function among complex refrovirus export proteins. Whereas HTV-l Rev and HTLV-1 
Rex inhibit the expression of both Tat and Rev specific mRNAs in facilitating the export of 
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incompletely spliced mRNAs, EIAV Rev specifically down-regulates its own production, 
independent of Tat, by promoting exon 3 skipping of the bicistronic mRNA (Figure 1) (13, 26). 
This mechanism allows for continuous production of Tat while Rev synthesis is limited. 
Although the mechanism by which the altemative splicing occurs has yet to be completely 
delineated, it has been proposed that binding of EIAV Rev to a RRE overlapping exon 3 
interferes with SR protein-RNA or SR protein-snRNP interactions (13). The disruption of SR 
protein binding is thought to result in exon 3 exclusion (13). This multi-functional nature of 
EIAV Rev highlights its importance in regulation of virus gene expression and replication. As 
such, genetic variation in Rev may have added significance in vivo. 
Rev is absolutely required for expression of lentivirus structural genes and production 
of new virus. Therefore, factors which modulate Rev activity and, consequentiy, alter levels of 
viral gene expression may be important in regulating virus replication in vivo. Rev-attenuated 
phenotypes have been identified during asymptomatic stages of HIV-1 infection, suggesting 
that variation in Rev could alter virus replication in vivo and contribute to the clinical outcome of 
infection (16, 18). It would be expected that viral phenotypes with highly competent Rev 
phenotypes would be present during periods of rapid virus replication; whereas, the production 
of "attenuated" or latent virus may be important for evasion of an active host immune resp>onse 
during periods of long-term persistence. Indeed, using multiple assays Hua et al. (16) showed 
that HIV-1 Rev clones obtained from asymptomatic infections were less functional than wild-
type Rev. Restricted expression of viral structural genes is a common strategy of persistent 
viruses (33), and these findings suggest that variation in Rev may be an important factor in 
lentivirus pathogenesis. We had previously identified extensive nucleotide substitutions in the 
Rev ORF from virus obtained from a horse experimentally infected with EIAV (1). The co­
existence of putative Rev-competent and Rev-deficient phenotypes suggested that variation in 
EIAV Rev may contribute to virus persistence through regulation of stmctural gene expression. 
The goal of the present smdy was to fiirther characterize genetic variation in EIAV Rev and to 
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determine if variation in EIAV Rev altered biological activity. 
Genetic variation in EIAV Rev. To fiarther explore the potential role of Rev variation 
in EIAV pathogenesis, we analyzed Rev cDNAs obtained from ceUs inoculated with either the 
Th-1, Th-6, or MA-1 virus isolates (Fig. 2A,B), as well as additional EIAV Rev sequences 
available in Genbank (Fig. 2C). Th-1 and Th-6 are field-derived virus isolates of EIAV 
recovered during the first and sixth febrile cycles, respectively, of a horse experimentally 
inoculated with whole blood from an EIAV-seropositive, naturally infected horse (1,6). MA-1 
is a cell-culture adapted, avirulent virus derived from Th-1 by in vitro passage in equine dermal 
(ED) cells (5,6). The analysis indicated a high degree of genetic variation in Rev exon 2. The 
sequences represent a variety of isolates and include virulent (Wyoming) and avirulent (MA-1) 
EIAV as well as in vivo (Th-1, Th-6) and in v/rro-adapted (MA-1) virus. Some of the sequences 
were derived from a single proviral clone isolated by limiting dilution and thus are representative 
of a predominant virus (i.e. P3.21), whereas other sequences represent quasispecies obtained 
following PGR amplification and cloning of viral cDNA or proviral DNA (Th-1.51). Numerous 
amino acid substitutions were found in the NES and in a 71 amino acid region in the center 
portion of the exon. The changes included deletions as well as amino acid substitutions, some 
of which resulted in the appearance of premature stop codons. In many cases, identical 
substitutions were found to re-occur, or to occur at specific amino acids, regardless of the virus 
isolate. Examples include valine/alanine at amino acid 105 and isoleucine/arginine/asparagine at 
amino acid 113. In other cases, a single change was diagnostic of a particular virus isolate. For 
example, all of the MA-1 quasispecies contained a glycine at amino acid 39, whereas cDNA 
clones from the related Th-1 virus, or the unrelated Wyoming strain of virus have an aspartic 
acid at that location. Also, the glutamine/serine amino acids present at amino acids 134 and 135 
were more frequent in MA-1 quasispecies, whereas the glycine to aspartic acid change at amino 
acid 115 was found only in the virulent Wyoming strain of EIAV. Within the NES, eighty 
percent of the variation occurred at amino acids reported to be necessary for Rev activity (25). 
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While it is possible that the observed variation in Rev is merely a consequence of random 
variation, or reflects selection for changes in the overlapping gp45 reading frame, recent 
findings suggest a role for Rev variation in the biology of EIAV in vivo. During successive 
febrile periods in a pony experimentally inoculated with EIAV, nucleotide and amino acid 
variation in EIAV Rev accumulated at approximately the same rate as that observed in gp90, and 
more frequently than was observed in gp45 or in the LTR (31). Taken together, these findings 
support the hypothesis that variation in EIAV Rev is biologically significant. 
Two independent RREs can mediate EIAV Rev-dependent export. To assess the 
functional activity of Rev variants, we developed an in vitro nuclear export assay similar to that 
widely used in ftinctional assays of other lentivirus Rev proteins (17, 25, 37). In other complex 
retroviruses, trans-acdvation of the Rev/Rex RNA export pathway occurs through an interaction 
with a single RRE (reviewed in 9). For the majority of lentiviruses, the RRE is located near the 
surface-transmembrane envelope region; two exceptions are FTV and HTLV-I, for which the 
RREs have been mapped near the 3' end of the genome (9,36,38). Surprisingly, previous 
studies have identified two cis-acting regions in EIAV which are able to act as RREs (15,26). 
However, specific binding of Rev has been shown with only one element overlapping the 3" end 
of the first rev exon (13). The exact location of the second RRE has not been identified and 
initial studies were performed to confirm the presence of two RREs. A pDMI38-derived 
reporter plasmid, pERRE-AU, was constucted by insertion of the CAT gene and a region 
containing all of the putative EIAV RRE sequences into an intron flanked by HTV-l splice sites 
(15, 17). Additional reporter plasmids were constructed containing EIAV regions previously 
shown to be able to act as RREs (26): pERRE-1 contains a short 5' RRE sequence overlapping 
the first Rev exon and pERRE-2 contains a major portion of the remaining downstream EIAV 
sequence present in pERRE-AU (15). The locations of the EIAV sequence present in the 
reporter constructs is shown in Fig. IB. For functional asssays, 293 cells were seeded in 
triplicate at 1-5 x 10^ cells/well in 6-well tissue culture dishes. The next day cells were 
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transfected with 0.2 |ig of reporter plasmid, 0.2 ^ig of beta-galactosidase expression plasmid 
pCHl 10 (Pharmicia, Uppsala, Sweden) or pSV-Pgal (Promega, Madison, WT) and 1 |j.g of an 
MA-1 Rev expression plasmid or empty vector. pUC19 DNA was added to bring the total 
amount of DNA transfected in each well to 2 |j.g. Cells were transfected using calcium 
phosphate co-precipitation and media was changed the next day. Two days posttransfection 
cells were harvested in phosphate-buffered saline (PBS) containing 5 mM EDTA, pelleted and 
resuspended in 300 jjJ 0.25 M Tris, pH 7.5, and lysed by three rounds of freeze-thawing. 50 [il 
of lysate was assayed for beta-galactosidase activity and these values were used to normalize 
lysates for CAT assays. Reaction volumes for CAT assays were equalized with 0.25 M Tris, pH 
7.5, to a final volume of 92 |il and incubated at 37°C with 5 |il 20 mM acetyl coenzyme A and 3 
|il of 50 mCi/mmole [i^Qchloramphenicol. Unacetylated and acetylated forms were separated 
by thin-layer chromatography and quantified using a Molecular Dynamics phosphoimager 
(Sunnyvale, CA). The percentage of acetylation was calculated for each transfection, and the 
data represents the average acetylation and standard error of the mean for all experiments. 
All three ERRE reporter plasmids were found to contain cis-acting elements able to 
mediate Rev-dependent RNA export (Fig. 3A). For purposes of comparison, results are 
presented as percent of activity found with pERRE-AU, which is shown as 100%. pERRE-1, 
containing the RNA element shown by Gontarek et al. to interact with GST-Rev in vitro (13), 
produced the majority (52%) of activity found with pERRE-AU. In contrast, assays with 
pERRE-2 resulted in only 17% of the activity seen with the pERRE-AU vector. There was also a 
low level of transactivation of the background vector, pDM138. These findings confirm 
previous studies indicating that EIAV Rev can mediate nuclear export through two separate 
RRE elements (26). In addition, they provide quantitative results which indicate that the primary 
RRE is contained within ERRE-1 and encompasses Rev exon 1. Although both RREs apprear 
to be required for maximum efficiency of the Rev-dependent export pathway, the significance of 
ERRE-2 as an important mediator of RNA export is questionable. The results presented here 
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suggest that ERRE-2 functions primarily as an enhancer of ERRE-1 rather than as an 
independent mediator of RNA export. Further studies are needed to more clearly ascertain the 
mechanism of the EIAV dual-RRE export pathway. 
Variation in Rev alters biological activity. To determine whether amino acid 
variation in Rev resulted in differences in biological activity, eight variant Rev cDNAs, four from 
MA-1 infected ED cells and four from Th-1 infected macrophages, were cloned into the 
eukaryotic expression vector pCR3 (Invitrogen, Carlsbad, CA) for functional analysis. Western 
blot analysis using Rev-specific polyclonal antibodies confirmed that all variants expressed at 
similar levels (data not shown). Variant cDNAs were assayed in transient expression assays by 
co-transfection with Rev reporter plasmids containing ERRE-All, ERRE-1, or ERRE-2 as 
described above. The results indicated that amino acid changes in the Rev ORF significantly 
altered biological activity (p < 0.0001) when both RRE elements were present (Fig. 3B). 
Variants ranged from being inactive (A22) to producing activities greater than three-fold that of 
MARev (H21). EIAV Rev variants F22, H21, and 27D4 were significandy more active than all 
other variants. In general, the range of biological variation was greater in the Th-1 derived Revs, 
consistent with the greater degree of sequence diversity observed among those clones as 
compared to the MA-1 derived clones. The results are consistent with studies analy2mg 
variation in HTV-l Rev (16) and support the hypothesis that biological changes in Rev activity 
may have significance in vivo. In addition, our results demonstrate that variation in regions 
outside the NES can also alter nuclear export activity. Because all assays were done using a 
single RRE sequence, we cannot rule out the possiblity that compensatory mutations in the RRE 
minimize the biological effects of Rev variation in vivo. Such analysis requires further mapping 
oftheEIAVRREs. 
Given the possibility of a synergistic interaction contributing to EIAV Rev-dependent 
export, we further characterized the effects of variation with the individual RREs by assaying the 
nine variants with both pERRE-1 and pERRE-2. Since the functional activity of the reporter 
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plasmids differs (Fig. 3A), the experiments with the separate reporter plasmids were performed 
using CAT assay conditions in which the acetylation of pcMARev lysates was approximately 
20%. Analysis of the individual Rev variants using the pERRE-1 reporter plasmid produced a 
similar pattern of activity relative to MARev as was observed with ERRE-AU (Fig.3B,C). 
However, with the exception of A22, the differences among the variants were less pronounced 
than observed with the pERRE-AU reporter plasmid. H21 was only two-fold more active than 
MARev, while 27A2 and 27D2 were slightiy more active relative to MARev. Surprisingly, the 
pattem of variation seen with pERRE-AU was abolished when the variants were assayed with 
pERRE-2 reporter plasmid (Fig. 3D). A22 was still inactive, but all other variants were more 
active than MARev and not significandy different from each other. Together, these results 
indicate that genetic variation in Rev alters biological activity, and that the effects of Rev 
variation are enhanced in the presence of both RREs. The mechanism(s) by which EIAV Rev 
utilizes two separate RREs are unknown, and it is not clear why the differences among the 
variants are decreased when only one RRE element is present. As suggested above, the 
downstream RRE may function primarily as an enhancer element of nuclear export mediated by 
RRE-1. If so, ±e effects of variation in regions of Rev important for interaction between RRE-1 
and RRE-2 may require the presence of both elements for observable differences in biological 
activity. 
Rev-dependent alternative splicing is not affected by variation. The current 
model of EIAV Rev dependent alternative splicing proposes that binding of Rev to the ERRE-1 
interferes with SR protein-RNA or SR protein-snRNP interactions to promote exon 3 skipping 
(13). The significance of this phenomenon in terms of virus replication is not known, although 
alternative splicing may play an important role in regulation of virus replication. Therefore, 
studies were undertaken to determine if the Rev sequence variants differed in splice-site 
utilization during EIAV mRNA processing. To analyze Rev-mediated altemative splicing 
patterns, we developed CfZTh cell lines stably transfected with a Rev-defective (Cf2Th/51) or 
31 
Rev competetent (Cf2Th/l 12) provims by G418 selection (data not shown). Cf2Th/51 cells 
were then trans-complemented with the variant cDNAs. Cells were seeded at 2 x 10^ cells/well 
in six-well tissue culture plates and transfected with 9 |ig of Rev variant plasniid or empty vector 
DNA by liposome-mediated transfection (Boehringer Manneheim, Indianapolis, E^T)- Two days 
post transfection RNA was isolated and cDNAs were amplified by RT-PCR using primers 
which spanned all EIAV splice-donor and splice-acceptor sites (5' primer: 
(CGCAGACCCTACCTGTTG (nt 354); 3' primer: TCTTCAGGTAACGACTGCC (nt 7301)) 
(Fig. 1). To allow for sensitive visualization of the splicing products, the 5' primer was 
[32p]end-labeled. RT-PCR was performed as described by the manufacturer (Perkin Elmer, 
Foster City, CA). PCR was performed with an annealing temperature of 55° and run for 25 
cycles. DNA from the RT-PCR reactions was phenol-chloroform extracted, ethanol precipitated, 
and resuspended in 40 |jJ 0. IX TE. 10 |jJ of each reaction was electrophoresed through a 
denaturing (7 M urea) 5% polyacrylamide gel. Gels were fixed, dried, then exposed to film for 
visualization. As a control. Rev mRNAs were amplified from transfected plasmids using pCR3-
specific primers (5' primer: ATACGACTCACTATAGGG; 3' primer: 
ATTTAGGTGACACTATAG). The results indicated both the 1,2,3,4 exon mRNA and the 
alternately spliced 1,2,4 exon mRNA were present in Cf2Th/l 12 cells and in all Cf2Th/51 cells 
trans-complemented with variant Rev cDNAs, including the functionally inactive A22 (Fig.4). In 
contrast, the 1,2,4 mRNA was not detected in Cf2Th/51 cells alone, or in cells trans-
complemented with vector DNA. The failure to detect differences in altemative splicing pattems 
suggests that variation present in the cDNAs we examined is not important for Rev-mediated 
altemative splicing. The finding that A22 was similar to other variant cDNAs in splice site 
utilization indicates the nuclear export ftmction of Rev is independent of exon 3 skipping. 
Therefore, these two fimctions most likely occupy separate domains in the protein, although 
both functions may require RRE binding. 
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Overall, our findings demonstrate that aa variation can enhance or attenuate EIAV Rev 
phenotype. Previous studies with HTV-l have shown that variation within the EDTV-l Rev NES 
can alter biological phenotype, and that the observed changes in function were consistent in both 
in vitro assays and studies of virus replication (16). We have demonstrated that variation in 
regions other than the NES can also modulate Rev activity in vitro. Given the extent of Rev 
variation we have observed, our results suggest that variation in Rev may be an important 
mechanism of modulating levels of virus replication during the course of clinical disease. 
Indeed, Leroux et al. reported rapid variation in Rev during sequential febrile cycles of a pony 
experimentally inoculated with EIAV (21). Functional Rev is absolutely required for production 
of infectious vims and it might be expected that Rev-defective, or Rev-attenuated, genotjfpes 
would be rapidly selected against during replication in vivo. However, factors which decrease 
Rev activity and decrease levels of viral gene expression may have a selective advantage and 
allow virus to persist in the face of an active host immune response. Further structural and 
functional analysis of in vivo derived variants at different stages of clinical disease are needed to 
delineate the role of Rev in disease pa±ogenesis. 
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FIGURE LEGENDS 
FIG. 1. Organization of the EIAV genome. (A) BCnown ORFs and predominant mRNAs 
isolated from virus-infected tissue culture cells (19). (B) Location of EIAV regions inserted into 
pDM138 CAT constructs (17). pERRE-AU contains nucleotides 5280 to 7534, pERRE-1 
contains a short 5' RRE sequence overlapping the first Rev exon (nucleotides 5280 to 5691), 
and pERRE-2 contains a major portion of the remaining downstream EIAV sequence present in 
pERRE-AU (nucleotides 5837 to 7534) (15). All numbering of nucleotides in the present report 
is based on Kawakami et al. (19). 
FIG. 2. Amino acid sequence aUgnments of Rev exon 2 (a.a. 31-165). (A) Amino acid sequence 
of exon 2 of MA-1 Rev (4) and amino acid sequences from cDNAs isolated from MA-1 
infected ED cells (ME) and MA-1 infected HMC (MM). (B) Amino acid sequences of cDNAs 
isolated from Th-1 infected HMC (A22, B11, F22, H21) and viral DNAs isolated from an 
EIAV(+) horse at the first and sixth febrile cycles (Th-1 and Th-6 respectively) (1). Missing 
sequences are due to use of an internal 5' primer for PCR amplification. (C) In vivo Rev exon 2 
sequences obtained from Genbank (Accession numbers: X63059, X16988, M14855, M18385, 
M18386, M18387, M18388, M87580, M93674). 
FIG. 3. In vitro assays of EIAV Rev activity. Transfection experiments were performed as 
described in the text. Two days post-transfection cells were harvested and lysates normalized 
for the CAT reactions by beta-galactosidase assay. Percentage of acetylation is shown. 
Individual experiments included triphcate wells and the data shown represents the mean of at 
least three separate experiments. Error bars denote the standard error of the mean for all 
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experiments. (A) Rev can trans-activate through two discrete regions of EIAV. pcMARev 
transactivation of CAT reporter plasmids pERRE-All, pERRE-1, pERRE-2, and pDM138. Each 
reporter plasmid contains the EIAV sequences shown in Fig. lb, pDM138 is the background 
reporter plasmid. Transfections and CAT assays were performed as described in the text, except 
that lysates from weUs with pERRE-All were diluted five-fold to allow for the comparison. (B) 
Transactivation of pDM138 CAT reporter plasmid pERRE-All by EIAV Rev variants showing 
that amino acid variation in Rev alters the biological activity of the protein. (C,D) Transactivation 
of pDM138 CAT reporter plasmids pERRE-1 (c) and pERRE-2 (d) by EIAV Rev variants 
indicating that the fuU effects of variation require both RRE regions. CAT assays were 
performed for each experiment with conditions that resulted in approximately 20% acetylation 
for the pcMARev lysates. Therefore, although the activities of the reporter plasmids differs, aU 
experiments appear on the same scale. 
FIG 4. Amino acid variation does not alter Rev-dependent alternative splicing. Rev-defective 
cells were transfected with 9 jig of variant Rev plasmids. Total RNA was isolated and reverse 
transcribed using random hexamer primers. cDNA was amplified by PCR with EIAV primers 
specific for exon 1 and exon 4 using a 5' primer that was [^"P]end-labeled. PCR products were 
isolated and separated by electrophoreses through a denaturing 5% polyacrylamide gel. The 
location of EIAV spUcing products is shown. As a control, mRNAs from transfected plasmids 
were amplified using pCR3-specific primers flanking the Rev insert. 
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CHAPTER 3. SEQUENCE VARIATION IN EQUINE INFECTIOUS ANEMIA 
VIRUS REV CORRELATES WITH VARIABLE STAGES OF CLINICAL DISEASE 
IN AN EXPERIMENTALLY INFECTED PONY. 
A paper to be submitted to the Journal of Virology 
Michael Belshan', Prasith Baccam'", J. Lindsay Oaks^, Brett A. Sponseller', 
Sean C. Murphy', James Comette" and Susan Carpenter' 
ABSTRACT 
Here we examine genetic and biological variation in the regulatory protein Rev of equine 
infectious anemia virus (EIAV) throughout a dynamic disease course of an experimentally 
infected pony. The pony underwent a variable disease course, including an acute fever 
episode at 12 DPI, multiple recurrent fever episodes until 135 DPI, a prolonged subclinical 
period, and two late fever episodes. Viral RNA was isolated from the inoculum and 
sequential sera samples, and the rev exon 2lgp45 overlapping ORFs were amplified, cloned, 
and sequenced. Novel variants were found throughout infection and genetic analysis 
indicated that both the rev and gp45 ORFs were under selective pressure. The Rev variant 
predominant in the inoculum, Rl, remained dominant during the acute period of infection 
(until 35 DPI). However, Rl was replaced by new dominant variants during the recurrent 
fever period (67-135 DPI). Rl re-emerged as the dominant variant during the period of 
subclinical infection. However, a new dominant variant, R93, was associated with the late 
fever episodes. In vitro analysis of Rev nuclear export activity indicated the dominant 
variants present during clinical periods were significandy more active than the variants 
dominant during the acute and subclinical periods. These results suggest Rev activity 
' Department of Microbiology and Preventive Medicine, Iowa State University 
^ Department of Mathematics, Iowa State University 
^ Department of Microbiology and Pathology, Washington State University 
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correlates with clinical disease and provide additional evidence that sequence variation in rev 
may be a contributing factor of EIAV pathogenesis. 
INTRODUCTION 
Equine infectious anemia vims (EIAV) possesses many of the characteristic features 
of the Lentiviridae subfamily of retroviruses, including a complex genome organization, 
tropism for cells of the monocyte/macrophage lineage, and establishment of a persistent, 
lifelong infection. Many lentivirus infections are characterized by a slow, chronic disease, 
but infection of horses with EIAV can result in an acute, dynamic disease course. The 
characteristic infection with EIAV involves recurring cycles of viremia, fever, and 
thrombocytopenia, with a possible development of anemia (reviewed in 19). Fever cycles are 
typically irregular and may last for up to one year, despite the onset of a neutralizing 
antibody response. Horses which survive these initial clinical episodes become life-long, 
inapparent carriers of the virus. 
Virus persistence over a life-long infection is dependent upon both host and virus 
factors. Genetic variation in lentiviruses, the result of errors produced by reverse 
transcriptase, is a well-smdied mechanism of lentivirus persistence (18, 22, 33, 37). Variation 
of the surface envelope protein, due to mutations, insertions, or duplications within the 
principal neutralization domain or hypervariable region, can alter antigenicity and allow 
evasion of host immune responses (20, 24-26, 32, 38-41,44, 51). Studies examining the 
immune responses of EIAV infected horses indicate both cellular and humoral immune 
responses contribute to suppression of viral replication during inapparent stages of infection 
(12, 44). However, no subset of the immune response has been shown to specifically 
correlate with control of virus replication during long term persistence (12). Therefore, other 
host and virus factors may be important determinants of virus persistence and pathogenesis. 
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Lentiviruses utilize complex mechanisms to regulate virus replication. Variation in 
regulatory elements which cilters the level of virus gene expression and subsequent 
replication may play an important role in disease. Genetic variation has been previously 
described in the second exon of the EIAV regulatory protein Rev (1,3). Rev facilitates the 
nuclear export of the incompletely spliced viral RNAs during the late phase of virus 
replication. These viral RNAs encode the structural proteins and provide progeny RNA 
molecules. Rev-dependent RNA export pathways have been described for numerous 
lentiviruses (reviewed in 8, 15), and the human immunodeficiency virus type 1 (HIV-1) Rev 
export pathway is the best characterized. HTV-l Rev binds a structure in the viral pre-mRNA 
called the Rev-responsive element (RRE) (50), multimerizes (36), then utilizes the CRMl 
nuclear export pathway to redirect movement of incompletely spliced RNA from the nucleus 
(5, 9,45,46). Discrete functional domains within the protein mediate the interactions of Rev 
with cellular proteins and viral RNA required for nuclear localization, RNA binding, 
multimerization and nuclear export. EIAV Rev is a 165 amino acid protein functionally 
homologous to HTV-l Rev (10). The nuclear export signal of EIAV Rev has been mapped to 
amino acids 32-55 (10) and has been shown to be able to substitute for the HTV-l or visna 
virus effector domains (10, 28). A putative nuclear localization signal has been mapped to the 
arginine rich C-terminus of Rev (13). 
Rev is absolutely required for expression of stmctural genes and production of new 
virus. Therefore, factors which modulate Rev activity and, consequently, alter levels of viral 
gene expression may be important in regulating virus replication in vivo. Rev-attenuated 
phenotypes have been identified during asymptomatic stages of HTV-l infection suggesting 
that variation in Rev could alter virus repUcation levels and contribute to the clinical outcome 
of infection (16, 21). We had previously identified extensive nucleotide substitutions in the 
second exon of EIAV rev in virus obtained from an experimentally infected horse (1). The 
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co-existence of putative Rev-competent and Rev-deficient phenotypes suggested tiiat 
variation in Rev may contribute to virus persistence through regulation of virus replication. 
Subsequent in vitro analysis indicated that limited amino acid variation in Rev could alter 
biological activity (3), fiirther suggesting variation in Rev may contribute to EIAV 
persistence and pathogenesis by modulating virus replication during disease. 
The present smdy characterizes genetic and biological variation in the second exon of 
EIAV rev during a long-term infection of an experimentaly-infected pony. Sequence analysis 
indicates a constant, but dynamic evolution of rev throughout disease. An in vitro assay used 
to measure the activity of Rev variants throughout disease demonstrates that Rev variants 
dominant in the recurrent and late fever periods displayed significantly more nuclear export 
activity than the variants dominant in the inoculum and subclinical periods of disease. These 
findings indicate that variation in rev correlates with clinical disease, and strongly argues that 
variation in rev is an additional factor contributing to the pathogenesis of disease caused by 
EIAV. 
MATERIALS AND METHODS 
Experimental infection. The experimental infection of pony 524 has been previously 
reported (35). The pony was infected with 10^ horse infectious doses of the highly virulent 
Wyoming strain of EIAV (EIAV^yo). Physical examinations, rectal temperatures, 
hemograms, and platelet counts were performed daily during clinical episodes and 
intermittently during chronic clinical disease or subcUnical infection. Serum and plasma were 
collected, processed, and stored at -80°C until analyzed. 
Virus neutralization assay. Assays were performed using equine dermal (ED) cells 
maintained in Dulbecco's modified eagle medium (DMEM) supplemented with 20% fetal 
bovine serum, penicillin, and streptomycin as previously described (7). ED cells were seeded 
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one day prior to infection at 10^ cells/well in a 6-well dish. Serum from pony 524 was heat 
inactivated at 60°C to destroy complement and serially diluted two-fold in supplemented 
media. Five hundred focus forming units of EIAV^su-s ^ 100 |j1 volume was incubated 
with 100 fil of serially diluted pony 524 serum at 37°C for I h. Duplicate wells of ED cells 
were inoculated with 100 ^il of virus-serum mixture in the presence of 8 |ig/ml polybrene, 
and the following day the media was changed. Cells were incubated for an additional 72 h, 
fixed with 100% methanol, and immunocytochemistry performed using convalescent anti-
EIAV horse sera to detect foci of virus-infected cells (7). Results are expressed as the serum 
neutralization titer, defined as the reciprocal of the highest serum dilution that gave a 80% 
reduction in foci as compared with preinmiune and negative control serum. 
Isolation of viral RNA. EIAVwy,, inoculum was obtained as a serum sample collected 
from an experimentally-infected foal at 7 days post-infection (DPI). To obtain viral RNA, 
100 |j.l of ELAVwyo inoculum or pony 524 serum was pelleted from by centrifugation at 
93,000 X g for 1 h at 4°C. Viral RNA was isolated from these pellets by guanidine 
thiocyanate lysis and acid phenol-chloroform extraction using a commercially available kit 
(Ambion, Austin, TX) and resuspended in 24 jil RNase-free glass distilled water containing 
0.1 mM EDTA. 
Amplincation and sequence analysis of viral variants. RNA samples were DNase 
treated using the methods of Huang et al. (17). Briefly, two units of DNase I (Ambion, TX) 
were added to 3 |jJ of viral RNA, 20 mM MgCU, 1 mM of each dNTP, IX PGR buffer II 
(Perkin-Elmer, Branchburg, NJ), 20 units of RNase inhibitor, and 2.5 mM of random 
hexamers in a total volume of 20 fil. The reaction was incubated at 37°C for 30 min and 
heated to 75°C for 5 min to inactivate the DNase. After cooling to 4°C, 50 units of Moloney 
murine leukemia virus reverse transcriptase were added. Reactions were incubated at 42°C 
for 45 min, heated to 99°C for 5 min to inactivate the reverse transcriptase, and then cooled 
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to 5°C for 5 min. The reaction was brought up to 100 jui in IX PGR buffer II with 2 mM 
MgClj, 0.2 mM of each dNTP, 2.5 units Taq pol5mierase (Perkin Elmer), and 1 (oM of each 
primer. Primers were designed based on conserved regions flanking the second exon of rev 
(Table 1). PGR amplification conditions consisted of 37 cycles of denaturation at 94°C for 2 
min, annealing at 50°C for 1 min, and extension at 72°C for 1 min. The initial and final 
cycles contained a prolonged extension at 72°G for 5 min. 2 |il of PGR product was TA-
cloned into pGEM-T vectors as recommended by the manufacturer (Promega, Madison, WI) 
and transformed into Escherichia coli DH-5a. Positive clones were identified by colony blot 
hybridization using a subgenomic fragment of rev labeled with [^"P]dTTP by random primed 
labeling (Roche Molecular Biochemical, Indianapolis, IN). Plasmids were isolated from 
positive clones using a commercially available kit (Promega), and the rev inserts were 
sequenced bi-directionally with vector primers flanking the insert. All sequencing was 
performed by the Iowa State University DNA Synthesis and Sequencing Facility using an 
automated DNA sequencer. Sequences were aligned by MacVector and AssemblyLIGN 
software (Oxford Molecular, Beaverton, OR). To estimate the RT-PGR error rate, viral 
mRNA was isolated and the second rev exon amplified from a clonal cell line stably 
transfected with an EIAV proviral DNA clone. The amplicons were cloned and 17 individual 
clones were sequenced. The error rate of the RT-PGR amplification procedure was 
determined to be 0.025%, or 3 substitutions per 11,991 base pairs sequenced. 
Construction of Rev Expression Vectors, rev variants were subcloned into 
pcRevWT, a Rev expression vector previously described as pcH21 (3). This plasmid contains 
a Rev cDNA in the pGR3 background (Invitrogen, Garlsbad, GA). pcRevWT was digested 
with the restriction endonuclease Apal to remove rev exon 2. The cut plasmid was gel 
purified, dephosphorylated, and Ugated with the exon 2 sequence variants. Two methods, 
based upon the direction of the inserts in pGEM-T, were employed to move variant exon 2 
51 
sequences into the pcRevWT background. Inserts in the "forward" direction were digested 
with Apal, gel purified, and ligated into the digested pcRevWT background. Inserts in the 
"reverse" orientation were PGR amplified with the EM7160 primer and a 3' EIAV primer 
containing an Apal site (underlined): 5'-CTGGGCCCTCATAAATGl"l"iCCTCCTTCGC. 
The PGR products were purified, digested with Apal, and ligated into the pcRevWT 
background. Ail clones were verified for directionality by restriction mapping and confirmed 
by sequencing. 
Statistical analyses. A two-dimensional chi-square test was used to test the null 
hypothesis that the frequency distribution of observed variants and the choice of primer pairs 
was independent. The chi-square statistic was calculated, and the p-value was determined for 
each contingency table. The statistical threshold used in this study was 95% confidence. 
Subset pairwise analyses were also performed on the data, and the results were interpreted 
with Bonferroni's correction (31). For the Monte Carlo simulation (43)to compare the four 
primer pairs, the chi-square distance was calculated between the four sets of simulated data. 
The data was simulated 10,000 times, and experimentally observed chi-square distances were 
compared with the 10,000 simulated distances to find the percentile ranking, which correlates 
to the p-value. For the pairwise analyses of primer pairs, 10 variants were randomly created 
for each set of the two simulated primer pairs. The rest of the simulation was the same as 
described immediately above, except the Kullback distance (4) was calculated rather than 
chi-square distance. 
Quantification of virus load. RNA quantification standards were synthesized by in 
vitro transcription from a linearized plasmid containing a 450-base pair fragment of EIAV 
gag, (pEIAp26.1). The RNA was purified by extraction with Trizol Reagent, treated with 6 U 
of DNase I (Ambion) for 45 min at 37°C to remove plasmid DNA, and then extracted again 
with Trizol Reagent. Final RNA preparation was quantified by spectrophotometry, aliquoted. 
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and stored at -80°C. The absence of contaminating plasmid DNA was verified by PGR 
without reverse transcription. 
To create standards, known copy numbers of RNA standards were assayed in 
triplicate as described below; these included 2 x 10^, 2 x 10®, 2 x 10^, 2 x 10*, and 2 x 10^ 
copies of RNA. Reaction products were visualized in ethidium bromide-stained agarose gels, 
and their densities quantified using a commercial digital imaging system (IS 1000, Alpha 
Innotech). The mean density for each copy number was plotted against the logio of the copy 
numbers to construct a standard curve. 
The one mbe, semi-quantitative RT-PCR protocol was modified from that described 
by Hamel et al (11). The reaction buffer contained 50 mM KCl, 10 mM Tris (pH 9.0), 0.1% 
Triton X-100, and 2.0 mM MgCl,, and each reaction contained 0.4 mM deoxyribonucleotide 
mix (Roche Molecular Biochemicals), 1 U of RNase inhibitor (Roche Molecular 
Biochemicals), 20 U of Moloney Murine Leukemia Virus reverse transcriptase (SuperScript 
n, Gibco BRL, Rockville, MD), 1.5 U of Taq DNA polymerase (Gibco BRL), and 90 pmoles 
of the forward primer (5'- ACTACTTGGGTGAATACCAT) and 90 pmoles of the reverse 
primer (5'- TCTGCCTAAACTGATCAAAA) in a final volume of 25 fjl. These 
oligonucleotides prime both reverse transcription as well as the subsequent PGR reaction, 
and amplify a 322 base pair segment of the EIAV capsid protein gene (p26) (nt 897-1199). 
Amplification was performed as follows: 42°G for 40 min, DNase I inactivation at 95°C for 3 
min, and 40 cycles of 94°C for 30 s, 58°C for 30 s, and 72°G for 30 s. Each RT-PCR run 
included positive and negative controls. Complete removal of all DNA from samples was 
confirmed by performing a duplicate reaction without reverse transcriptase. Following 
amplification, 13 ^1 of the PGR reaction was analyzed by electrophoresis through 2.0% 
agarose and visualized by ethidium bromide staining and ultraviolet light. Serum samples 
from each time point were assayed in duplicate, and their mean density values were used to 
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calculate copy numbers of viral RNA from the standard curve. RT-PCR reactions for 
standards and samples were performed simultaneously using a reagent-master mix, and were 
analyzed simultaneously in a single agarose gel. 
CAT Assays. 293 cells were maintained in Dubelco's modified eagle medium 
supplemented with 10% fetal calf serum and penicillin/streptomycin. Transient transfections 
and CAT assays were performed using 293 cells as previously described (3). Briefly, 1 |ig of 
either pcDNA3 or Rev variant plasmid was transfected by calcium phosphate co-
precipitation with 0.2 |ig of pERRE-All reporter plasmid, 0.2 ^ig of pCHl 10 (Amersham 
Pharmacia Biotech, Piscataway, NJ), and 0.6 (ig of pUC19. pERRE-All, a derivative of 
pDM138 containing EIAV nt 5280-7534, has been described previously (3). Each 
experiment also included a sham group which contained no reporter plasmid, but an 
additional 0.2 (ig of pUCI9. Two days posttransfection, cells were harvested, resuspended in 
0.3 ml 0.25 M Tris (pH 7.5), lysed by freeze/thawing, and assayed for P-galactosidase 
activity to normalize CAT assays for transfection efficiency. Normalized lysates were 
assayed for CAT activity in a 0.1 ml volume with 3 |il [''^CJcliloramphenicol and 1 mM 
acetyl CoA. Acetylated products were separated by thin layer chromatography and the 
percentage of acetylation determined by quantification by phosphorimager. Experiments 
were performed in triplicate and results summarize a minimum of nine independent 
transfections. Statistical significance was determined by analysis of variance. 
RESULTS 
Clinical profile of EIAVwyo-infected pony 524. To accurately reflect the diversity of 
an in vivo infection, pony 524 was inoculated with a highly virulent Wyoming strain of EIAV 
(EIAVwyo)> which has been maintained by serial in vivo passage (35). This inoculum 
represents a heterogeneous population of virus, similar to a natural infection. After 
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inoculation, pony 524 experienced a clinical disease course characterized by recurring fever 
cycles interspersed with afebrile periods ranging from days to months (Fig. 1 A). The initial 
acute episode was characterized by a bi-phasic febrile response and thrombocytopenia from 
10 to 22 days postinfection (DPI). The pony was then afebrile until 39 DPI. Thereafter, pony 
524 underwent a period of seven recurrent fever episodes, which ranged from two to six days 
in length. The last fever episode ended after day 135, and pony 524 remained afebrile except 
for two late fever episodes at days 565 and 799. Febrile episodes were defined as rectal 
temperature greater than or equal to 10l°F. Thrombocj^openia (platelet count less than 1 x 
10^ platelets/^.1) was also observed concurrent with the initial fever cycles. Surprisingly, after 
the initial fever cycles subsided, pony 524 remained persistently thrombocytopenic 
throughout the experiment. Except for the fever and thrombocytopenia, no other clinical 
signs were observed. 
Semi-quantitative RT-PCR was used to monitor virus levels at various DPI (Fig. IB). 
Consistent with previous reports, high virus loads were found in the initial fever period at 12 
DPI, but fell to a nearly undetectable level during the afebrile interval at 35 DPI. The highest 
virus load, 9.08 x 10^ copies RNA/ml, was detected during the recurrent febrile period at 67 
DPI. Levels of plasma viral RNA decreased somewhat in the subclinical period and were 
barely detectable at 754 DPI. However, virus rebounded to 1.38 x 10^ copies/ml at 800 DPI. 
Serum neutralization assays to EIAV^su-s. a ceU culmre derived strain of EIAVwyo (34) 
indicated that broadly reacting neutralizing antibodies appeared after the chronic fever cycles 
subsided (201 DPI) (Fig. IC). Pony 524 maintained strong neutralizing antibody to 
EIAVwsu-5 throughout the remainder of the infection. 
Quasispecies distribution of the inoculum and statistical analysis of sampling 
procedure. The overall goal of these studies was to examine rev variation at successive 
stages of clinical disease. A potential problem with current methods used to characterize viral 
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variants is the possible selection of a sub-population of variants that may not be reflective of 
the population present in vivo. To confirm that the selected primer pairs did not bias the 
distribution of observed variants, statistical analysis was performed on the distribution of 
variants obtained by RT-PCR amplification of the inoculum. These sequences were amplified 
using four different sets of primer pairs, designed from conserved regions flanking exon 2 of 
rev (Table 1). A total of 61 individual clones, at least ten from each primer pair, were 
sequenced from the EIAV^yo inoculum. Thirty-eight different genotypes and 25 different Rev 
amino acid variants, designated R1 through R25, were observed (Fig. 2). Five genotypes 
were observed at a frequency greater than one, and two clones, R1 and R2, accounted for 
30% and 25% of the sample population, respectively. These results indicated that the 
distribution of rev genotypes in the inoculum was not random. 
A chi-square analysis testing the null hypothesis that the frequency distribution of the 
variants was independent of the primer pairs did not detect any statistically significant 
differences at either the nucleotide (p=0.31) or amino acid level (p=0.35). Six pairwise chi-
square analysis using Bonferroni's correction (31) also failed to detect statistical significance 
at either the nucleotide level or the protein level. The lack of significant bias due to primer 
pair choice suggests the observed quasispecies population is reflective of the in vivo 
population. However, the sample sizes in the majority of ceUs in the contingency tables were 
lower than desired for chi-square analysis. Therefore, a Monte Carlo computer simulation 
(43) was performed to evaluate the validity of our chi-square analysis (Table 2). The 
comparison of all four primer pairs produced p-values of 0.30 and 0.36 at the nucleotide and 
protein levels, respectively. Simulations checking the pairwise chi-square analyses also 
produced p-values similar to those obtained by the chi-square analysis. The results of these 
simulations corroborated the chi-square analysis and further indicated that the selected PCR 
primer pairs did not bias the data obtained. Therefore, the frequency and distribution of the 
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Rev variants obtained by RT-PCR can be considered representative of the virus genotypes 
present in vivo. 
Genetic changes in revlgp45. To analyze Rev variation throughout infection, RNA 
was isolated from sera samples at various stages of clinical disease including: Acute febrile 
(12 DPI), first afebrile interval (35 DPI), recurrent febrile (67, 89, and 118 DPI), afebrile 
(201, 289, 385, and 437 DPI), and late febrile (754 and 800 DPI) periods. Twenty-two to 
twenty-six rev exon 2/gp45 clones were amplified from each time point using primer pairs 2 
and 3. Sequences from each time point represent data from two independent RT-PCR 
reactions. Genetic analysis indicated the transition (Ts) to transversion (Tv) ratio was high at 
each time point (Table 3), consistent with observations of other retroviruses (23). The overall 
Ts/Tv ratio for the region was 6.7 and application of the Tajima test (49) confirmed that 
variation in this region was due to selective pressure (p < 0.01). The ratio of non-
synonymous (Kn) to synonymous (Ks) mutations was greater than one in both ORFs at each 
time and the overall Kn/Ks ratio was 1.54 for rev and 2.15 for gp45. Together, these data 
indicate that both rev and gp45 were under selective pressure throughout infection. Novel 
variants were detected at each time point; however, the appearance of new variants was more 
rapid during clinical periods. The greatest number of new variants for both rev and gp45 was 
observed at 67, 89, 118, and 201 DPI, corresponding to the middle and end of the recurrent 
fever period. Conversely, fewer novel genotypes were observed at 289, 385, 437, and 754 
DPI, periods of sub-cUnical infection. These results demonstrate that changes in the 
frequency and distribution in both ORFs correlated with the different stages of clinical 
disease. 
Rev variant distribution throughout clinical disease. There were marked changes 
in the frequency and distribution of the Rev aa variants obtained from successive stages of 
clinical disease (Fig. 3). Overall, variation was observed throughout the exon with the 
57 
exception of aa 89-99 and conserved changes in the C-terminus (e.g. R to K). In nine of the 
eleven time points there was a predominant variant that was identical to the consensus 
sequence for that time point. Indeed, the majority of variants from a particular time point 
were generally similar to the dominant variant. The predominant Rev variant in the 
inoculum, Rl, also occurred at the greatest frequency in the samples from the acute fever 
episode (12 DPI) and subsequent afebrile period (35 DPI) suggesting that the inoculum 
phenotjfpe was maintained early in infection. Several changes in the distribution of Rev 
variants occurred during the recurrent fever period. Notably, Rl was not detected during the 
recurrent fever period and two of the three time points had new dominant variants- R32 at 67 
DPI and R53 at 118 DPI. No variant predominated at 89 DPI, however the consensus 
sequence was similar to the consensus sequences at 67 and 118 DPI. The change in Rev 
frequency and distribution during the recurrent febrile period suggests a shift occurred in 
selective pressure. At 201 DPI, the first serum sample analyzed after the febrile episodes 
subsided, Rl was observed again, but no variant was dominant. Rl became the major variant 
at 289 DPI and predominated throughout the remainder of the afebrile period (385 and 437 
DPI) .  Hence ,  i t  appeared  tha t  another  change  in  se lec t ive  pressure  occurred  tha t  favored  Rl .  
After the late fever episode at 565 DPI, a new variant, R93, arose as the dominant variant at 
754 and 800 DPI. Although Rl was still observed at 754 DPI, it was not detected at 800 DPI 
sugges t ing  another  sh i f t  in  pressure ,  s imi lar  to  the  recurrent  per iod ,  tha t  se lec ted  agains t  Rl .  
The dynamics of Rev evolution are highlighted by the disappearance and reappearance of the 
Rl variant which dominated early after infection and in the afebrile period, but was replaced 
by novel variants during both the recurrent and late febrile episodes. This clearly 
demonstrates that different selective pressures were present at distinct stages of clinical 
disease. 
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The activity of dominant Rev variants correlates with clinical disease. To assess 
if there was a correlation between Rev activity and state of clinical disease, the exon 2 
cDNAs of the Rev variants dominant throughout the infection were cloned into a eukaryotic 
expression vector containing exon 1 of rev and their nuclear export activity determined using 
a transient transfection assay with a pDM138 reporter vector, pERRE-AU (Fig. 4) (3). All 
assays were normalized to Rl, the variant dominant in the inoculum, the acute fever period 
(12 DPI), first afebrile interval (35 DPI), and the afebrile period (289, 385, and 437 DPI). R2, 
a variant which contained a single aa change from Rl and was generally observed at the 
same time points, exhibited a similar level of activity to Rl. Interestingly, all other variants 
assayed showed significantly higher levels of nuclear export activity as compared to Rl and 
R2 (p < 0.001). These included variants dominant or co-dominant at 67, 89, 118, 754 and 800 
DPI, time points during or near clinical episodes. All of these variants exhibited 
approximately 150% activity relative to Rl, except R17, which displayed 125% of the 
activity of Rl. Together, these results demonstrate that Rev variants with higher activity are 
associated with periods of clinical disease (Fig. 5), indicating that variation in Rev may be 
an important factor of EIA disease pathogenesis. 
DISCUSSION 
Antigenic variation has long been recognized as an important mechanism of 
retrovirus persistence and pathogenesis. Recent studies suggest that variation in viral 
regulatory elements, including the LTR and accessory genes, also contributes to clinical 
disease (3, 6, 16, 27, 30). We previously observed a high degree of genetic variation in the 
rev exon 2lgp45 region of EIAV (3, 27) and demonstrated that limited amino acid variation 
in Rev alters biological activity (3). To delineate the significance of rev variation in vivo, we 
have examined sequence variation in an experimentally-infected animal. Discrete genetic and 
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biological changes were observed in Rev dnring sequential stages of an EIAV infection and 
genetic analysis demonstrated that the rev ORF evolved throughout infection. The evolution 
of rev quasispecies was highest during clinical periods, concomitant with higher levels of 
virus replication. Furthermore, changes in the frequency and identity of dominant Rev 
variants correlated with changes in clinical disease. The nuclear export activity of the Rev 
variants dominant during the recurrent febrile episodes was significantly higher than the 
activity of the variants predominant during the acute febrile or afebrile periods. Together, 
these findings argue that variation in rev may be a contributing factor of EIA disease 
pathogenesis. 
Viremia has long been associated with clinical episodes in EIAV-infected animals 
(19). The abrogation of recurrent clinical episodes is typically co-incident with the 
maturation of the host immune response and decline in virus replication (12). Thus, we 
would expect that an absence of immune selection in the recurrent febrile period should favor 
an increase in viais load, whereas immune pressure in the afebrile period should result in a 
decrease of virus load. Although the appearance of broadly acting neutralizing antibody in 
pony 524 at 201-289 DPI was associated with the resolution of the febrile period, we did not 
observe the expected drop in virus load. Because Rev regulates virus replication, the 
observed increase in virus load from 35 to 67 DPI is consistent with the replacement of R1 
by variants with significandy higher levels of nuclear export activity during the recurreat 
febrile period. However, viremia remained high until late in the afebrile stage of disease (754 
DPI), despite the re-emergence of the less active R1 at 201 DPI. Therefore, it is not 
surprising that we did not observe variants less active than R1 in this period. Overall, 
changes in the activity of the dominant Rev variants did not correlate with virus load as well 
as with clinical disease in pony 524. It is possible that Rev variants less active than R1 might 
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have been detected if pony 524 had resolved to a "typical" subclinical state in which virus 
load decreased to near undetectable levels. 
It is generally accepted that sequence variation in overlapping reading frames is much 
more constrained than variation in sequences with a single ORP. However, a previous report 
examining human immunodeficiency virus type I (HTV-l) variation in the revlgp41 
overlapping ORFs suggested that despite such constraints, both genes evolved independently 
(29). Our data would suggest the opposite for the EIAV revlgp45 overlap. Several lines of 
evidence support this hypothesis. First, the evolution of both ORFs was surprisingly similar 
throughout infection. The rate of appearance of new rev and gp45 variants was most frequent 
in both ORFs during periods of high virus replication. Second, out of 146 nt variants, there 
was a similar number of total Rev and gp45 aa variants (101 and 105, respectively). Third, 
the overall diversity (number of aa variants at each time point) of rev and gp45 was 
approximately the same throughout infection. Finally, with the exception of 35 DPI, all 
dominant Rev variants were associated with a single gp45 variant. The only evideace that 
would suggest a divergent evolution is the fact that at seven of the eleven time points, there 
was a higher increase in the number of new rev variants than gp45 variants. Therefore, we 
argue that the evolution of rev and gp45 is convergent, and therefore we cannot rule out that 
changes in gp45 also contribute to the selective advantage of the observed Rev variants. 
Hence, variation in both regions may be an important determinant of virus pathogenicity in 
vivo. 
The underlying assumptions of the RT-PCR method are that all viral quasispecies are 
amplified with equal efficiency and the resulting proportions are representative of the starting 
population. While these assumptions have generally been accepted, some reports suggest that 
PCR amplification might result in selective amplification of individual templates, especially 
in reactions containing a heterogeneous population of templates (2, 42,47,48). Previous 
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stxidies have suggested that interactions between primers and templates might alter the 
efficiency of template amplification and thus alter the sample population (2, 14, 48), or that 
primer pairs may systematically bias PGR amplification (2,42,48). However, these studies 
have generally involved 2 or 3 different templates of known concentrations. The complex 
nature of viral quasispecies in vivo can further complicate sequencing studies. Our statistical 
analysis of the inoculum overcomes such complexities and shows that the primer pairs we 
used for PGR amplification did not alter the frequency of observed variants. The risk of bias 
may have been reduced by designing primers to conserved target sequences and using 
primers with similar GG-content and optimal annealing temperatures (Table 1). Taken 
together, our results suggest that randomly sampled viral populations obtained by RT-PGR 
can reflect in vivo populations. This offers confidence in the characterization of viral 
populations present in vivo, and strengthens interpretations of studies involving the role of 
virus variation in immune evasion and disease progression. 
Many previous in vivo studies of EIAV variation have used a cloned, cell-culture 
propagated virus as an inoculum. Such an inoculum typically represents a homogenous 
population of virus. While such studies have been useful in identifying genetic changes that 
arise during an in vivo infection, our intention was to better reflect a naturally occurring 
infection in an experimentally-infected animal. Therefore, the inoculum used was obtained 
from a donor pony undergoing its first fever cycle and represented a heterogeneous 
population of virus instead of a single clone. Although this method required a more extensive 
analysis, we believe it provided an accurate representation of the complex nature of EIAV 
evolution throughout disease. The heterogeneous nature of the inoculum, in combination 
with the extensive genetic analysis at sequential time points, allowed us to fiilly evaluate the 
genetic and biological phenotype of Rev variants that were selected at variable stages of 
clinical disease. It is clear from this analysis that genetic and phenotypic changes in Rev 
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correlated with changes in clinical stages of disease. The corresponding changes in the 
activity of the dominant Rev variants during the febrile periods provides strong evidence that 
variation in Rev can confer a selective advantage in vivo. 
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TABLE 1. Primer pairs used for amplification of EIAV Rev sequences 
Primer Primer Primer GC O.A.T. 
Pair Name" Sequence (5'-3') content(%) "Co 
EM 7066 CAATTTGGCACAATCCATGA 40 
1 EM 7674C GCGAGAGTTCCTTCTTGGGC 60 55.7 
EM 7066 CAATTTGGCACAATCCATGA 40 
2 EM 7680C GGAATTCCGAGAGTTCCTTCTTGG 50 55.7 
EM 7160 GGATTGGGAGCTTCCATTAT 45 
3 EM 7674C GCGAGAGTTCCTTCTTGGGC 60 55.5 
EM 7160 GGATTGGGAGCTTCCATTAT 45 
4 EM 7680CRI GGAATTCCGAGAGTTCCTTCTTGG 50 55.5 
indicates the primer is on the complementary (anti-sense) strand, and R1 indicates the 
presence of an EcoKl restriction site (underlined) at the 3' end. 
''Optimal annealing temperature for PGR amplification. 
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Table 2. Pairwise analyses testing independence of primer pairs and the frequency 
distribution of observed quasispecies* 
Primer pairs Nucleotide Protein 
analyzed Variants Variants 
CS'' MC" CS'' MC" 
I and 2 0.34 0.14 0.65 0.68 
1 and 3 0.25 0.42 0.27 0.22 
1 and 4 0.65 0.44 0.27 0.25 
2 and 3 0.36 0.46 0.29 0.25 
2 and 4 0.49 0.27 0.61 0.64 
3 and 4 0.17 0.13 0.07 0.05 
"P-values derived from chi-square analysis. 
""P-values derived from Monte Carlo simulation. 
*Using Bonferroni's correction, these p-values are compared to 0.0083 for interpretations at 
the 95% confidence level. Thus, none of the pairwise analyses is statistically significant. 
Table 3. Genetic Analysis of rev and gp45 ORFs 
DPI 
IN 12 35 67 89 118 201 289 385 437 754 800 Total 
Total 
Clones: 
61 24 23 23 24 24 25 22 26 23 24 23 322 
#Variants 25 7 11 13 18 11 16 8 12 6 7 8 
Rev New 
Variants 
25 6 7 9 14 8 12 3 7 1 5 4 101 
2.2 6 7 4.3 4.5 3 3 2.2 2.8 4 3.5 1.6 1.5 
# Variants 30 7 10 14 16 11 15 8 10 12 8 11 
gp45 New 
Variants 
30 5 4 11 12 7 10 2 4 6 5 9 105 
Kn/Ks' 3.5 #2 11 6 4 3.2 8.3 6.5 5.3 14 8.5 11. 2.1 
'Ratio of non-synonymous to synonymous mutations in that ORF 
"No non-synonymous changes present in gp45 at that time point 
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FIGURE LEGENDS 
FIG. 1. Clinical and serological profile of pony 524. (A) Clinical profile of EIAV^yo- infected 
pony 524. Platelet counts (gray line, primary y axis) and periods of fever (columns, 
secondary y axis) were monitored as described in Materials and Methods. Fever was defined 
as rectal temperature greater than or equal to 101 °F. (B) Virus load, as measured by copies of 
RNA/ml serum, was determined by semi-quantitative RT-PCR for the days indicated by open 
circles. (C) EIAV^su-s neutralizing antibody (VN) titers of pony 524. VN titers were 
determined as described in Materials and Methods from serum samples obtained at 0, 11, 35, 
67, 89, 118, 201, 289, 498, 754, and 800 DPI. 
FIG. 2. Amino acid distribution of Rev sequences in EIAVwryo inoculum. Twenty-five 
variants were obtained from 61 total clones sequenced. The frequency (N) and variant 
identity (V) are given. The aa sequence of the dominant variant (Rl) is given, and the 
sequence of all other quasispecies are below: (.) Indicates an identical aa to Rl at that 
position and (-) indicates a -1 frameshift mutation. 
FIG. 3. Alignment of Rev aa sequences obtained from sera of pony 524 at 12, 35, 67, 89, 
118, 201, 289, 385, 437, 754, and 800 DPI. The frequency (N) and variant identity (V) are 
given for each time point, as well as the total number of clones sequenced (below the N 
colurrm). Dominant variants are highlighted in bold. Sequences are compared to Rl, which is 
listed at the top of each time point. For individual sequences (.) indicates an identical aa to 
Rl at that position, (*) indicates a premature stop codon in the rev ORF, and (+) indicates a 
+1 frameshift. 
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no. 4. In vitro biological activity of Rev variants from pony 524. Rev exon 2 variants were 
inserted into a eukaryotic expression vector and transient transfection assays were performed 
in 293 cells as described in the Materials and Methods. CAT assays were normalized to the 
activity of R1 and the results are presented as a percentage of activity compared to Rl. Error 
bars denote the standard error of the mean. 
FIG. 5. Variation in EIAV Rev correlates with clinical disease. A summary of (A) the 
activity of dominant Rev variants and (B) rectal temperature of pony 524 at various DPI. On 
days with no dominant variant (i.e. 89 and 201 DPI), the relative activity was determined as a 
weighted average of the most frequently occurring variants. 
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CHAPTER 4. BINDING OF EQUINE INFECTIOUS ANEMIA VIRUS REV TO AN 
EXON SPLICING ENHANCER MEDIATES ALTERNATIVE SPLICING AND 
NUCLEAR EXPORT OF VIRAL MRNAS 
A paper submitted to the journal Molecular Cellular Biology 
Michael Belshan', Patricia Bilodeau", Gregory S. Park*, C. Martin Stoltzflis", 
and Susan Carpenter' 
ABSTRACT 
In addition to facilitating the nuclear export of incompletely spliced viral mRNAs, equine 
infectious anemia virus (EIAV) Rev regulates alternative splicing of the third exon of the 
tat/rev mRNA. In the presence of Rev, this exon of the bicistronic RNA is skipped in a 
fraction of the spliced mRNAs. In this report, the cis-acting requirements for exon 3 usage 
were correlated with sequences necessary for Rev binding and transport of incompletely 
spliced RNA. The presence of a purine-rich exon splicing enhancer (ESE) was required for 
exon 3 recognition, and the addition of Rev inhibited exon 3 splicing. GST-Rev bound to 
probes containing the ESE, and mutation of GAA repeats to GCA within the ESE inhibited 
both exon 3 recognition in RNA splicing experiments and GST-Rev binding in vitro. These 
results suggest that Rev regulates alternative splicing by binding at or near the ESE to block 
SR protein-ESE interactions. A 57 nt sequence containing the ESE was sufficient to mediate 
Rev dependent nuclear export of incompletely spUced RNAs. Mutation of the ESE 
significantly reduced Rev export activity indicating the ESE fimctions as a Rev responsive 
element (RRE). Together, these results demonstrate that EIAV Rev mediates exon 3 
exclusion through protein-RNA interactions required for efficient export of incompletely 
spliced viral RNAs. 
' Department of Veterinary Microbiology and Preventive Medicine, Iowa State University 
* Department of of Microbiology, University of Iowa 
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INTRODUCTION 
Retroviruses utilize a variety of mechanisms to differentially express numerous 
proteins from relatively small genomes which possess a single transcriptional start site. These 
mechanisms include, but are not limited to, the use of polyprotein precursors, ribosomal 
frameshifting (19), alternate start codons (7), bicistronic mRNAs (7), and alternative splicing 
(28). Alternative splicing allows for the production of multiple viral mRNAs from a single 
RNA precursor. The simplest retroviruses, such as murine leukemia virus, express only two 
mRNAs, an unspliced RNA which serves as both mRNA for the Gag and Pol proteins and as 
progeny viral RNA, and a singly spliced mRNA which encodes the env gene. In contrast, 
complex retroviruses, such as human immunodeficiency virus type 1 (HTV-l) produce at 
least 20 different mRNAs, including several multiply spliced RNAs that encode small 
regulatory proteins (28). 
In all retroviruses, alternative splicing requires the presence of suboptimal splice 
sites, allowing for expression of several mRNAs from a single pre-RNA. Regulation of 
suboptimal splice sites is a complex process mediated in part by cw-acting RNA sequences 
that can either enhance or repress recognition of a splice site by the splicing machinery. Exon 
splicing enhancers (ESEs) and silencers (ESSs) have been described for many virus and 
cellular RNAs (2, 22). ESEs typically are purine rich sequences embedded within 
alternatively spliced exons. The purine rich sequences mediate exon recognition through 
interactions wi± members of the SR protein family of splicing factors. SR proteins are both 
essential splicing factors and regulators of alternative splicing (reviewed in 17). Binding of 
SR proteins to an ESE recruits essential splicing factors to suboptimal splice sites near ESE 
sequences resulting in exon inclusion of alternatively spliced exons. 
In addition to the above mechanisms, complex retroviruses utilize Rev-like pathways 
to differentially regulate expression of incompletely spliced RNAs encoding for virion 
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structural and enzymatic proteins and progeny RNA molecules (reviewed in 10). The 
prototype member of this family, HTV-l Rev, binds to the viral pre-mRNA at a specific 
sequence called the Rev-responsive element (RRE) (9, 34), multimerizes (23, 33), and 
facilitates export of incompletely spliced RNAs from the nucleus via a nucleoporin pathway 
distinct from that used by cellular mRNAs (14,15). Equine infectious anemia virus (EIAV) 
Rev is functionally homologous to HIV-1 Rev (16), but is less well characterized. EIAV Rev 
is a 165 amino acid protein translated from exons 3 and 4 of a multiply spliced, 4-exon, 
bicistronic mRNA which also encodes the trans-activating protein. Tat (Fig. 1) (7). In 
addition to promoting nuclear export of incompletely spliced RNA, EIAV Rev also regulates 
inclusion of exon 3 of the multiply spliced RNA. In the presence of Rev, a multiply spliced 
mRNA lacking exon 3 is produced (21). Exon 3 is flanked by a suboptimal splice acceptor 
and contains a purine rich, exon splicing enhancer-Uke motif which has been shown to 
interact with the SR protein ASF/SF2 (IB). This has suggested that Rev-mediated skipping of 
exon 3 may result from a disruption of ESE-SR protein interactions (18). We previously 
mapped a RRE of Rev to a 534 nt region containing exon 3 (4). This suggested the possibility 
that Rev mediates exon 3 skipping by binding at or near the purine rich sequence to disrupt 
SR protein interactions necessary for exon 3 recognition. 
Here, we further delineate the role of Rev in exon 3 alternative splicing. Our results 
indicate that the purine rich sequence in exon 3 is required for the utilization of the exon 3 
splice acceptor, confirming the presence of an ESE within exon 3. RNA gel mobility shift 
assays and nuclear export assays demonstrate that Rev binds to the ESE, and that this binding 
facilitates RNA export. Together, these results indicate the exon 3 ESE is a RRE of EIAV. 
Therefore, Rev mediates exon 3 alternative splicing by binding the viral pre-mRNA and 
interfering with SR protein — ESE interaction. 
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MATERIALS AND METHODS 
PCR and Plasmid construction. All plasmid constructs were confirmed by sequence 
analysis (Iowa State University DNA Synthesis and Sequencing Facility). DNA templates for 
splicing substrates were amplified from pSSk, a subclone of the p26 EIAV pro viral clone 
previously described (6). Unless otherwise indicated, PCR reactions were performed as 
directed by the manufacturer (Perkin Elmer, Foster City, CA) using 1 foM primers. Standard 
PCR reactions consisted of 25 cycles of one minute denaturation at 94° C, one minute 
annealing at 50°C, and one minute extension at 72° C, followed by an addition cycle with a 
prolonged, five minute extension. AH DNA templates for splicing substrates used a common 
5' primer, CTGAAGGCAATCCAACAAGG; and individual 3' primers to generate the 
substrates shown in figure 2A. The 3' primers used and the region of EIAV amplified were: 
CTCTCTATGATAAGCTTC, EIAV nt 5233-5793; CCAGTAGTTCCTGCTAAGCA, nt 
5233-5573; TTTCCACCAGTCATTTCTTC, nt 5233-5535; CAGGTTCATTTCTTGGTCT, 
nt 5233-5490. All nucleotide numbering is based on that of Kawakami et al. (20). After PCR, 
fragments were TA cloned into the pGEM-T easy vector as directed by the manufacturer 
(Promega, Madison, WT). 
The expression plasmid pRevWT was described previously as pcH21 (4). pDM138, 
pERRE-AH (EIAV nt 5280-7534), and pERRE-1 (nt 5280-5834) have also been previously 
described (4). To construct pERRE-lA, primers containing a Clal restriction site were used 
to amplify EIAV nt 5281-5795. ERRE-IA 5' primer: 
GGATCGATTTGATATATGGGATTATT; 3' primer: 
GGATCGATCTCTCTATGATAAGCTTC {Clal sites are underUned). The minRRE 
sequence (EIAV nt 5485-5540) was synthesized as complementary oligonucleotides with 
Clal extensions on the 5' and 3' ends. The oligonucleoddes were heated at 95° C for 5 min 
and annealed by slow cooling. The fragment was phosphorylated, then ligated with pDM138. 
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The pGST-Rev expression vector contains a cDNA cloned in frame into the BamSil site of 
the GST fusion vector pGEX-3X (Amersham Pharmacia Biotech, Piscataway, NJ). 
ESE mutants were constructed by PCR-Ligation-PCR mutagenesis according to the 
methods described by Ali et al. (1) using internal primers designed with the specified 
mutations shown in figure 4A. The two regions were amplified with Vent DNA polymerase 
(New England Biolabs, Beverly, MA). The 3' fragment was phosphorylated, ligated with the 
5' fragment, and 2 ^1 of the ligation reaction was PGR amplified with outer primers described 
above to amplify EIAV nt 5233-5793. Amplicons were cloned into pGEM-T. To construct 
the mutant pDM138 constructs, the pERRE-lA primers described above were used to PGR 
ampify the respective mutants from the pGEM-T background and clone into the Clal 
restriction site of pDM138. 
Synthesis of RNA substrates. The plasmids containing the spUcing substrates were 
digested with Spel (GIBGO BRL, Rockville, MD) to create linearized templates for 
transcription of RNA splicing substrates. In vitro run-off RNA transcripts labeled with 
[^-P]UTP (Amersham Pharmacia Biotech) were generated as previously described (2). DNA 
templates for RNA binding analysis were amplified by PGR from p33k using 5' primers 
containing a T7 promoter site (a diagram of the substrates is in Fig. 3 A). The primers used 
for the substrates were: 5' primer: 
TAATAGGAGTGAGTATAGGGAGGAACAGGATGGGAGAATGG. 3' primer; 
TTTGGAGGAGTGATTTGTTG (RREpl, nt 5443-5535); 5' primer: 
TAATAGGAGTGAGTATAGGGAGGTGAAAGAAGAATGTAAAG. 3' primer: 
GGAGGAAAGTATTGGTGG (BlREp2, nt 5489-5589); 5' primer: 
TAATAGGAGTCAGTATAGGGAGGTGACTGGTGGAAAATAGG.3' primer: 
GGGTATATAATGTTGGTG (RREp3, nt 5523-5622); 5' primer: 
TAATAGGACTGAGTATAGGGAGGGGGAGGAAGGAAGAGAGG, 3' primer: 
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CCTGCTAAGCATAACAGA (RREp4, nt 5458-5565). The T7 promoter is underlined in the 
5' primers. Amplified DNA was phenolrchloroform extracted, ethanol precipitated, and 
resuspended in RNase-free dH20. The RREp5 DNA fragment was synthesized as two 
complementary oligonucleotides containing the T7 promoter attached to EIAV nt 
5485—5540. Complementary DNA fragments were combined at equal molar amounts, heated 
at 95° C for 5 min then slow cooled to armeal. 
Expression/Purification of GST-Rev. BL21 Escherichia coli transformed with the 
pGST-Rev expression vector was grown overnight at 1/10 final culture volume in NZY broth 
containing 0.1 mg/ml ampicillin. The next day, cells were brought up to final volume, grown 
an additional 3 hours, then expression of GST-Rev induced with 1 mM IPTG for 5 h. After 
induction, cells were washed 3 times and resuspended in 50 mM Tris (pH 8.0), 50 mM NaCl 
(TN buffer). Cells were lysed by sonication and the supernatant clarified by centrifugation at 
10,000 xg. GST-Rev was purified by binding to glutathione sepharose 4B beads (Amersham 
Pharmacia Biotech) overnight and washed 3X with TN buffer. The fusion protein was eluted 
with 15 mM reduced glutathione in 50 mM Tris, pH 8.0, concentrated with a 30 kDa MWCO 
filter concentrator (Millipore, Bedford, MA), and dialyzed against TN buffer. Protein 
expression was confirmed by SDS-PAGE and immunoblotting with convalescent anti-EIAV 
antisera or anti-GST antisera (Amersham Pharmacia Biotech) which detected expression of 
the GST-Rev fusion protein and several minor bands, including GST alone (data not shown). 
In some cases, the fiision protein was digested with 4 units/bead bed volume of Factor Xa 
protease (Amersham Pharmacia Biotech) while bound to glutathione sepharose beads. Excess 
GST and GST-Rev fusion protein were removed with the glutathione sepharose beads, and 
the supernatant, containing cut Rev protein, concentrated and dialyzed as described above. 
In vitro splicing, and gel electrophoresis. Splicing reactions were carried out as 
previously described (2). In brief, approximately 8 fmol of EIAV RNA substrates were 
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incubated for 2 hours at 30°C with 60% (v/v) nuclear extract in Dignam's buffer D (13), 20 
mM creatine phosphate, 3 mM MgCl2, 0.8 mM ATP and 2.6% (w/v) polyvinyl alcohol. In 
some experiments, EIAV Rev protein was diluted in buffer D (13) and added to the splicing 
reactions at the indicated concentrations. RNAs were analyzed on 4% polyacrylamide gels 
containing 7 M urea. 
RNA binding Assays and gel electroplioresis. RNA — protein interactions were 
performed in IX RNA binding buffer containing 10 mM HEPES-KOH (pH 7.5), 100 mM 
KCl, 1 mM MgCU, 0.5 mM EDTA, 1 mM DTT, 50 |J.g/|il E. coli tRNA, and 10% glycerol. 
RNA was in vitro transcribed in the presence of [^"P]IJTP as described above. 100 ng to 2 mg 
of GST or GST-Rev fusion protein was incubated with approximately 1 x 10® cpm RNA 
probe on ice for 15 minutes. The reactions were directly loaded onto a 8% native 100 mM 
tris-glycine polyacrylamide gel (37.5:1 acrylamiderbis cross-linking ratio) which had been 
pre-run 1 hour. The samples were electrophoresed an additional 3 hours. The gel was fixed in 
20% ethanol, 10% acetic acid for 15 minutes, dried, and exposed to X-ray film with an 
intensifying screen. 
CAT Assays. 293 human embryonic kidney cells were maintained in Dulbecco's 
modified eagle medium supplemented with 10% fetal calf serum and penicillin/streptomycin. 
Transient transfections and CAT assays were performed using 293 cells as previously 
described (4). Briefly, 1 ng of either pcDNA3 (Invitrogen, Carlsbad, CA) or pRevWT was 
transfected by calcium phosphate co-precipitation with 0.2 jig of pDM138 reporter plasmid, 
0.2 p.g of pCHl 10, and 0.6 ng of pUC19. Each experiment also included a sham group which 
contained no reporter plasmid, but an additional 0.2 |ig of pUC19. Two days 
posttransfection, cells were harvested, resuspended in 0.3 ml 0.25 M Tris (pH 7.5), lysed by 
freeze/thawing, and assayed for P-galactosidase activity to normalize CAT assays for 
transfection efficiency. Normalized lysates were assayed for CAT activity using 3 ^1 
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["^C]chloramphenicol and 1 mM acetyl Co A. Acetylated products were separated by thin 
layer chromatography and the percentage acetylation was quantified by phosphorimager 
(Molecular Dynamics, Sunnyvale, CA). Experiments were performed in triplicate and results 
summarize a minimum of six independent transfections. 
RESULTS 
The purine rich sequence is required for exon 3 recognition. Exon 3 of the 
bicistronic, four exon, equine infectious anemia virus (EIAV) mRNA contains a purine rich 
sequence which resembles an exon splicing enhancer (ESE). Previous reports showed that 
the SR protein ASF/SF2 cross-links to the ESE-like sequence in vitro and suggested the ESE-
like sequence may enhance exon 3 inclusion during pre-mRNA splicing (18). To investigate 
the cis-acting requirements for exon 3 inclusion, we constructed a series of DNA templates to 
generate radiolabeUed RNA substrates for in vitro splicing. All substrates contained the exon 
2 splice donor, the intervening intron, exon 3, and downstream sequences. Nested 3' 
deletions were made to identify splicing enhancer sequences present within or downstream of 
exon 3 (Fig. 2A). Splicing of radiolabeUed substrates was assayed in vitro using HeLa cell 
nuclear extracts, which include all SR proteins. All constructs containing the purine rich 
sequence were spliced (Fig. 2B, lanes 3-5), whereas no splicing was observed using the 
substrate lacking the purine rich sequence (Fig. 2B, lane 2). This is consistent with the 
hypothesis that the purine sequence functions as an ESE and is required for exon 3 inclusion 
in the multiply spliced four exon transcript. Taken together with previous work (18), this 
suggests exon 3 recognition requires ASF/SF2 interactions at the ESE. The addition of as 
little as 100 ng of Rev to a splicing reaction containing the largest splicing substrate inhibited 
exon 3 recognition (Fig. 3). This confirms earlier, in vivo observations of Rev-mediated 
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changes of alternative splicing, and indicates that Rev is the only viral protein necessary for 
exon 3 skipping. 
Rev binds the ESE. Disruption of ASF/SF2-ESE interaction by Rev could occur 
either by direct interaction of Rev with ASF/SF2 or by binding of Rev to a region of the viral 
pre-mRNA near the ESE. In previous work, we identified an RRE region spanning exon 3 (nt 
5280 to 5834) (4). This favors a mechanism wherein Rev-RRE interactions disrupt ASF/SF2 
binding at the ESE. To examine whether Rev binds at or near the ESE, we generated a series 
of RNA probes and tested for Rev-RNA interactions by RNA gel mobiUty shift assays using 
a bacterially expressed and purified GST-Rev fusion protein. The location of the RNA probes 
relative to exon 3 and the ESE is shown in figure 4A. GST-Rev bound to exon 3 probes 
RREpl and RREp2, which both contain the ESE; however, no binding was observed with the 
GST negative control (Fig. 4B, lanes 1 to 4). Minor binding was observed with RREp3 (Fig. 
4B, lane 6), which has sequences immediately downstream of the ESE (nt 5523 to 5622), but 
lacks the purine rich region. The binding site was further deUneated to a 57 nt region of viral 
RNA using two smaller ESE-containing probes, RREp4 and RREp5. GST-Rev interacted 
with both probes (Fig. 4B, lanes 8 and 11), further suggesting that Rev binds at or near the 
ESE. To confirm the specificity of binding, gel shift assays were performed with RREp2 in 
the presence of excess cold competitor RREp2 or RREp3 (Fig. 4C). Excess cold RREp2 
inhibited GST-Rev binding (Fig. 4C, lanes 2 and 3), whereas no inhibition was observed with 
RREpS (Fig. 4C, lanes 4 and 5), demonstrating that the binding of GST-Rev to the ESE-
containing RREp2 is specific. No slower migrating bands, indicative of Rev multimerization, 
were observed in any of the RNA binding analysis, although multimerization was readily 
observed with HTV-l Rev when used as a positive control (data not shown). The minor bands 
in figure 4C represent GST-Rev and degraded by-products. Overall, these results suggest that 
Rev specifically interacts with the viral RNA at or near the ESE. 
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Mutagenesis of the ESE reduces exon 3 splicing and Rev binding. The finding that 
GST-Rev bound to a 57 nt region containing the ESE suggested that a Rev-RNA interaction 
was directly competing with ASF/SF2 for binding at the ESE. If so, there should be similar 
sequence requirements for exon 3 recognition and Rev binding. The ESE contains two purine 
rich sequences (designated A and B), which include seven GAA repeats (Fig. 5A). GAA 
repeats have been shown to be important for ASF/SF2 recognition of ESE sequences in other 
systems (reviewed in 17). Therefore, we constructed five ESE mutants in the largest splicing 
construct and the RREp4 RNA probe fragment which contained various GAA to GCA 
mutations (Fig. 5A). The mutant templates were tested for in vitro splicing and GST-Rev 
binding. Mutation of all GAA motifs (mutAll) or the B purine stretch (mutB) resulted in a 
decrease in both exon 3 in vitro splicing (figure 5B, lanes 3 and 5) and in GST-Rev binding 
(figure 5C, lanes 2 and 4). Mutation of only two of the four GAA repeats in the B purine 
stretch resulted in a more modest reduction in both in vitro splicing and GST-Rev binding 
(Fig. 5B, lanes 6 and 7 and 5C, lanes 5 and 6). Mutation of GAA repeats in the A region 
(mutA) did not appear to significantly affect either exon 3 splicing or GST-Rev binding in 
vitro (Fig. 5B, lane 4 and 4C, lane 3) suggesting the B purine stretch alone contains cis-
acting sequences necessary for exon 3 recognition and GST-Rev binding. The finding that 
each mutant had comparable effects in both assays suggests similar requirements in the ESE 
for both exon 3 recognition and Rev binding. These results support a model of Rev inhibition 
of splicing through direct competition with SR proteins for binding at the ESE. 
The ESE can function as a RRE to mediate RNA nuclear export. In other 
complex retroviruses. Rev functions to regulate the export of incompletely spliced RNAs via 
interaction with the viral pre-mRNA at a specific sequence called the Rev responsive element 
(RRE). We had previously used the pDM138 reporter system to preliminarily map the RRE 
of EIAV to a region which overlapped exon 3 (ERRE-I, nt 5280-5834) (4). However, this 
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fragment possessed only 52% of the activity of a reporter containing a much larger fragment 
of EIAV (EBURE-All) suggesting further downstream sequences enhanced Rev-mediated 
export. The RNA binding data given above suggested that the functional sequence within 
ERRE-1 was the ESE sequence. To test this, we constructed a pDM138 reporter plasmid, 
minRRE, which contains only 57 nt of EIAV (RREp5, nt 5485-5540), spanning the ESE and 
the remainder of exon 3. Transient transfection assays in 293 cells demonstrated the minRRE 
reporter produced levels of CAT activity comparable to ERRE-1 (Fig. 6A), but only 35% of 
the activity obeserved with ERRE-All. This indicates minRRE contains the functional RRE 
in ERRE-1, however additional elements outside ERRE-1 may be required for full export 
activity. 
To confirm the ESE is the RRE within minRRE, we introduced the GAA to GCA 
mutations used for in vitro splicing and RNA binding assays (Fig. 5A) into a reporter vector 
containing the same sequences present in the largest splicing substrate (Fig. 2A). This vector, 
ERRE-1 A, although 41 nt shorter than ERRE-1, exhibited similar levels of activity as ERRE-
1 (Fig. 6A). In aU cases, mutation of the GAA repeats in the ESE significantly reduced Rev 
dependent nuclear export activity (p < 0.01) (Fig. 6B). The greatest reduction in activity was 
seen in constructs containing mutations of all seven GAA repeats (mutAll) or the three 
repeats in the A purine stretch (mutA). The reduction in activity in mutA indicates this 
region, while not necessary for GST-Rev binding, is required for RNA nuclear export. 
Mutations in the B region (mutB, B12, B34) also significandy reduced activity (p < 0.01). 
Therefore, we conclude that the B purine stretch functions in GST-Rev binding, exon 3 
inclusion, and Rev-dependent nuclear export. Together, these results indicate the ESE 
sequence acts as an RRE and that Rev mediates alternative splicing by binding at or near the 
ESE to disrupt ASF/SF2 interactions. 
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DISCUSSION 
These studies demonstrate that the purine rich sequence within exon 3 of equine 
infectious anemia virus (EIAV) is both an exon splicing enhancer (ESE) and a functional Rev 
responsive element (RRE). The use of an ESE as an RRE is unprecedented among complex 
retroviruses. A prior study demonstrated that the SR protein ASF/SF2 cross-links in vitro 
with exon 3 and suggested that the purine rich sequence was an ESE (18). Consistent with 
this previous data, we show the purine rich sequence is required for exon 3 recognition in 
splicing reactions in vitro. Taken together, these data suggest ASF/SF2 is the SR protein 
required for efficient splicing of exon 3. The ability of a 57 nt sequence containing the ESE 
to interact in vitro with GST-Rev and act as a functional RRE in a heterologous nuclear 
export assay system demonstrates that this region contains a functional EIRE. Mutation of 
GAA nucleotide repeats in the ESE reduced GST-Rev binding, exon 3 splicing in vitro, and 
nuclear export of ESE containing pre-mRNA. Therefore, both exon 3 splicing and Rev-
mediated RNA export have similar ci^-acting RNA requirements. We propose that Rev-
mediated nuclear export requires binding at or near the ESE. This results in skipping of exon 
3 through an inhibition of ASF/SF2 - ESE interactions required for recognition of exon 3 by 
the host cell splicing machinery. 
It is interesting that mutation of the 5' purine stretch (mutA) decreased nuclear export 
but appeared to have little effect on GST-Rev binding in vitro. Studies with HTV-l Rev also 
indicate that sequences in the HTV-l RRE are required for nuclear export but not RNA 
binding (24, 25). While these observations have not been fully explained, it is likely that 
RNA secondary structure plays a role. Secondary structure is a key determinant for HIV-1 
binding, multimerization, and function (8 ,9, 11, 12, 23, 24, 26). Since no biochemical data is 
available to date on the structure of the EIAV ESE/RRE, it is not possible to determine the 
structural effects of the mutations used in our study. Our data would suggest that mutation of 
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the 5' purine stretch does not affect the primary binding site of Rev, but may alter distant 
structures required for Rev-mediated nuclear export. It has been demonstrated that HIV-1 
Rev multimerization occurs only after binding to a primary site on the RNA and other 
regions of the RNA are important for secondary binding (9, 11, 31). However, we were 
unable to observe Rev multimerization in our RNA binding assays, including those assays 
containing the ESE. Therefore, it remains unclear why mutA exhibited reduced activity with 
no apparent defect in RNA binding. It is also possible that binding of host cell proteins to the 
RRE may be required to facilitate Rev export activity. Further studies will be necessary to 
delineate the role of this purine region in Rev-mediated nuclear export. 
Interactions of Rev-like proteins with SR proteins have been demonstrated in other 
complex retroviruses. SR proteins have been shown to bind the HTV-l RRE in a Rev-
dependent manner (27). The same study also demonstrated that excess exogenous ASF/SF2 
could produce a dose-dependent inhibition of HTV-l Rev function in vivo. We have 
previously reported an inhibition of EIAV replication in activated macrophages associated 
with a delay in the appearance of incompletely spliced RNAs (30). The data presented here 
would suggest this inhibition may be a result of competition of ASF/SF2 with Rev for 
binding at the ESE. In support of this hypothesis, preliminary data in our laboratory has 
shown that excess ASF/SF2 provided in trans can inhibit Rev function in transient 
transfection assays and reduce virus particle production from a proviral containing cell line 
(5). Together, these results suggest the inhibition in activated macrophages may be due to an 
increase in the level of SR proteins. It is known that expression of SR proteins varies in cells 
at different states of activation and differentiation (17,29, 32), including an increased 
expression of the SR protein SRp30c in activated T-cells (29). However, little is yet known 
about the phenotype of SR proteins in monocyte cells. Also, our data carmot rule out the 
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possibility that in addition to competing for binding at the RRE, Rev may also inhibit 
ASF/SF2 function via protein-protein interactions. 
Whether altemative splicing of exon 3 is merely a consequence of Rev-mediated 
nuclear export or plays an important role in virus replication has not been determined. The 
RREs of most complex retroviruses are located near the SU-TM cleavage site or in the 3' end 
of env. The location of EIAV RRE in the 5' env is unique, and may be explained by the 
requirement of the ESE for exon 3 inclusion. The env mRNA is spliced using the exon 2 
splice acceptor (Fig. 1). A singly spliced mRNA using the exon 3 splice acceptor has not 
been observed in infected cells, and would encode a truncated Env protein lacking the signal 
peptide. A singly spliced mRNA using the exon 4 splice acceptor is observed, which 
produces a truncated transmembrane protein from the alternate start codon present in exon 1. 
Therefore, the use of an ESE as an RRE may function to silence recognition of exon 3 to 
eliminate another singly spliced transcript. Although a number of retroviruses utilize ex­
acting sequences such as ESEs to take advantage of cellular mechanisms of altemative 
splicing, EIAV appears to be the only retrovirus to encode a trans-zcXmg protein that directly 
modulates SR-mediated altemative splicing. EIAV was the first described lentivims and is 
smaller and genetically less complex than the other lentivimses. It is possible that the EIAV 
Rev-ESE interaction may represent a transitional step in the evolution of the Rev-Rex 
pathway utilized by most complex retroviruses. Interestingly, previous work in our 
laboratory and others suggested that EIAV may possess two separate RREs (4, 21). In the 
current study, reporter constructs containing the 57 nt ESE region showed significantly 
reduced activity as compared to the ERRE-AU reporter constract containing a larger portion 
of the env gene (Fig. 6A). However, a second RRE element has not been identified, nor is it 
clear that such an element can function independently of the ESE to mediate export of viral 
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pre-mRNAs. Additional studies will help to fully understand the biological and evolutionary 
significance of the EIAV Rev-mediated export pathway. 
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FIGURE LEGENDS 
Fig. 1. Organization and splicing patterns of EIAV. Schematic of EIAV genome with ORFs. 
The tat ORFs are indicated with a't', the first exon of rev with a 'r' (location in genome is 
indicated by the shaded region). SpUcing patterns and genes expressed are indicated. The ttm 
ORF encodes a truncated transmembrane protein of unknown function (3). 
Fig. 2. Exon 3 splicing requires the purine rich sequence. (A) Diagram of RNA substrates 
used for in vitro splicing showing the location of exons 2 and 3. All substrates contain the 
exon 2 splice donor and exon 3 splice acceptor. Approximate location of purine rich 
sequence is indicated by the hatched box. (B) After incubation for 2 h in HeLa cell splicing 
extracts, RNA products were electrophoresed through 4% polyacrylamide gels and visualized 
by autoradiography. Location of spliced and unspUced products is shown. 
Fig. 3. Rev inhibits exon 3 splicing. GST-Rev or GST was added at the indicated 
concentrations to the splicing reactions. Location of the splicing products is indicated. 
Fig. 4. GST-Rev binds the ESE in exon 3. (A) Location of RNA probes, relative to exon 3, 
used in RNA gel mobility shift assays. The purine rich ESE sequence is indicated by the 
hatched box. (B) After incubation with GST or GST-Rev, radiolabelled RNAs were 
electrophoresed through 8% native polyacrylamide gels. Location of GST-Rev-RNA 
complexes is indicated with an arrow. (C) Competition assays were performed with either 0.5 
or 1 ng of the indicated excess cold competitor RNAs. Competitors were mixed with GST-
Rev 10 min prior to the addition of radiolabelled probe. 
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Fig. 5. In vitro splicing and RNA binding of ESE mutants. (A) Sequence of two purine 
stretches (designated A and B) in exon 3. GAA repeats were mutated to GCA in largest 
splicing construct (Fig. 2A) and RNA probe RREp4 (Fig. 4A). (B) In vitro splicing analysis 
of mutant ESE constructs. Location of splicing products is indicated. (C) RNA gel mobility 
shift assays detecting GST-Rev binding to the mutant probes. 
Fig. 6. EIAV ESE can fiinction as an RRE. (A) pDM138-derived reporter vectors containing 
various regions of the EIAV genome. Transient transfections and CAT assays were 
performed as described in Materials and Methods. The results are presented as the percentage 
acetylation. Experiments were performed in triplicate and the results represents at least nine 
independent transfections. Error bars denote the standard error of the mean. (B) ESE 
mutations indicated in figure 5A were also introduced in the ERRE-IA reporter vector and 
assayed for CAT activity in the presence or absence of Rev as described above. 
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CHAPTER 5. MAPPING THE ALTERNATIVE SPLICING DOMAIN OF EQUINE 
INFECTIOUS ANEMIA VIRUS REV 
A selection from a paper that will be submitted to the journal Virology 
Michael Belshan, Sean C. Murphy, and Susan Carpenter 
INTRODUCTION 
Complex retroviruses (e.g. HTV-l, EIAV) are classified as exhibiting temporal 
regulation of gene expression during infection of a cell. The early phase is characterized by 
the presence of small, multiply-spliced mRNAs encoding virus regulatory proteins (Fig. 1). 
For EIAV, these proteins include Tat and Rev. Tat, a transcription transactivator, increases 
the level of viral RNA transcription up to 1000-fold. Tat acts by binding a structure near the 
transcription initiation site in the newly synthesized viral mRNA (called the TAR element) 
and increasing the processivity of transcription (7). The regulatory protein Rev post-
transcriptionally regulates the expression of incompletely spliced viral mRNAs that code for 
virion structural proteins, envelope glycoproteins, and provide for progeny RNA molecules. 
Upon reaching a threshold concentration in the host cell. Rev facilitates a switch from the 
early gene expression to late gene expression by directing the nuclear export of the 
incompletely spliced viral RNAs. In the absence of Rev, virus replication does not occur. 
Rev-dependent RNA export pathways have been described for numerous retroviruses 
(reviewed in 8), and the HTV-l Rev-mediated RNA export pathway is the best characterized. 
HTV-l Rev enters the nucleus, binds a structure in the viral pre-mRNA called the Rev 
Responsive Element (RRE) (6, 14, 24), multimerizes (15, 16, 20, 23), then utilizes a non-
mRNA nuclear export pathway to redirect movement of incompletely spliced RNA from the 
nucleus (4,9, 10,22). Discrete functional domains within the protein mediate the interaction 
of Rev with both cellular proteins and the viral RNA These domains include nuclear 
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localization, RNA binding, multimerization and nuclear export. 
EIAV Rev is a highly charged, 165 amino acid protein translated from a bicistronic 
four exon mRNA coding for both Tat and Rev (Figure 1) (5,21). Though functionally 
homologous to HIV-1 Rev, EIAV Rev shares little amino acid homology. The nuclear export 
signal (NES) of EIAV Rev has been mapped to amino acids 31-55 (11), and domain 
swapping experiments have shown that this region of EIAV Rev can substitute for the HTV-l 
or visna virus NES (4, 17, 19). A putative nuclear localization signal has also be mapped to 
the arginine rich C-terminus of the protein (13). 
EIAV Rev also has an additional, apparently unique function among complex 
retrovirus Rev-like proteins. Whereas HIV-1 Rev and human T-ceU leukemia virus-1 Rex 
inhibit the expression of both Tat and Rev specific mRNAs in facilitating the export of 
incompletely spliced mRNAs, EIAV Rev specifically down-regulates its own production, 
independent of Tat, by promoting exon 3 skipping of the bicistronic mRNA (Fig. 1) (12, 18). 
This mechanism allows for continuous production of Tat while Rev synthesis is reduced. 
Inclusion of exon 3 in the mRNA requires the interactions of SR proteins with an exon 
splicing enhancer (ESE) within the exon sequence (3, 12). Rev mediates exon 3 skipping by 
binding to a RRE overlapping exon 3, which interferes with SR protein-ESE interactions 
required for exon 3 inclusion. The multi-functional nature of EIAV Rev highlights its 
importance in regulation of virus gene expression and replication. As such, genetic and 
biological variation in Rev may have added significance m vivo. 
Here we present a functional mapping of EIAV Rev by deletion analysis. In vitro 
assays of Rev activity revealed that the protein is highly sensitive to deletions. Analysis of 
Rev mediated alternative splicing indicated that amino acids 75-127 of the protein are 
important for exon 3 skipping. The ability of a NES-deficient Rev mutant to still mediate 
alternative splicing demonstrated that these two functions of Rev are independent. 
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RESULTS 
Construction/Expression of Rev deletion mutants. A series of deletion mutants of 
EIAV Rev was constructed to map domains essential for Rev activity (Fig. 2A). Deletions 
were constructed by PCR-ligation-PCR mutagenesis (1) and cloned into the eukaryotic 
expression vector pCRS.l. Deletions were confirmed by sequence analysis, then protein 
expression confirmed by Western blot analysis of transiently transfected cells using 
convalescent anti-EIAV horse sera (Fig. 2B). The Western blot results indicated that ail 
cDNAs express Rev and would be usable in in vitro assays. However, not all mutants 
expressed Rev at comparable levels. Ail those with alternate start codons (e.g. Al-11, Al-19, 
A1-30) appeared to express Rev at lower levels. Changes in apparent protein levels could 
have also resulted from decreased antibody reactivity to proteins with deletions (e.g. AlOl-
113). 
Functional analysis of Rev deletion mutants. To determine the effects of the 
various deletions on Rev nuclear export activity, we functionally assayed the Rev mutants 
with a reporter construct, pERRE-AU, in which the CAT gene and a region containing 
putative EIAV RRE sequences are flanked by HTV-l splice sites (2, 14). Since Rev inhibits 
splicing, the production of CAT is proportional to the activity of the Rev. Functional assays 
were performed using transient expression assays as previously described (2). Briefly, 293 
human embryonic kidney cells were seeded in triplicate in 6-weU tissue culture dishes and 
transfected with mutant Rev cDNA or empty vector, reporter plasmid, and beta-galactosidase 
reporter plasmid. Two days posttransfection cells were harvested, resuspended in 300 |il Tris 
buffer, and lysed by three cycles of freeze-thawing. 50 |i,l of lysate was assayed for beta-
galactosidase activity and these values were used to normalize lysates for CAT assays. CAT 
assays were performed using [''*C]chloramphenicol and unacetylated and acetylated forms 
were separated by thin-layer chromatography and quantified using a phosphorimager 
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(Molecular Dynamics). The percentage of acetylation was calculated for each transfection, 
and the average acetylation and standard error of the mean were calculated for all 
experiments. 
To use a more relevant biological method to measure Rev mutant activity, we 
developed a virus complementation assay. This method utilizes a canine fetal thymus 
(Cf2Th) cell line stably transfected with a Rev-defective EIAV pro virus (Cf2Th/51 cells) (2). 
Cf2Th/51 cells were rran^-complemented with the Rev mutants and the release of virus 
particles into the cell supernatant was measured using a [^"P]-based assay for the detection of 
reverse transcriptase activity. C£2Th/51 cells were transfected with each Rev mutant and 
three days post-transfection 100 |il of supernatant sampled. To assay reverse transcriptase 
activity, 10 |JI of the supernatant was lysed and reverse transcriptase activity measured by the 
incorporation of [^"PITTP onto a poly(rA) template. Incorporation was measured using a 
phosphorimager. Assays were performed in triplicate and standard error of the mean 
calculated. 
Results from both assays are shown in figure 3. Overall, the analysis indicated that 
Rev is highly sensitive to deletion mutagenesis. Almost all of the mutants exhibited 
decreased activity in comparison to wild-type Rev. Only one mutant (A131-143) retained 
wild-type levels of activity in both assays. Certain mutants (Al-19, Al-30, A164-165) may 
have decreased activity due to poor expression. However, other mutants (A75-82, A144-165) 
expressed at higher levels and stUl remained non-functional, indicating that the loss of 
activity was likely due to deletion of an important functional domain. Loss of activity did not 
consistently correlate with the observed expression levels firom Western blots. The C-
terminus of the protein contains a highly conserved KRRRK motif which has been proposed 
to be the nuclear localization signal (NLS) of Rev (13). Deletion of this region or the center 
portion (aa 75-127) of the protein proved highly deleterious, and therefore demonstrates both 
I l l  
domains are important for fimction. The center region, aa 75-127, contains two basic regions 
and is predicted to be a-helical in structure. Therefore, it is likely that this region contains 
motifs important for RNA binding and multimerization. 
Amino acids 75-127 are required for Rev mediated alternative splicing. The 
current model of EIAV alternative splicing proposes that exon 3 skipping is mediated by 
disruption of an interaction between SR-proteins and an exon splicing enhancer (ESE) 
sequence in exon 3 by the binding of Rev to an RRE in the same region (3, 12). To determine 
the ability of each deletion mutant to promote exon 3 skipping, splicing patterns were 
determined in Cf2Th/51 cells /rflt/zj-complemented with each of the mutants. Cf2Th/51 cells 
were transfected with each mutant and total cellular RNA was isolated three days post-
transfection. [^"P]End-labeled RT-PCR was employed to detect the presence/absence of the 
alternative sphced mRNA (Fig. 4). Trans-complementation with wild-type Rev resulted in 
approximately 50% alternative splicing versus a positive control cell line (Cf2Th/l 12) 
containing a Rev-competent pro virus (approximately 17% alternative splicing) (Fig. 4). 
The results demonstrated that the center portion of the protein (aa 75-127) is required 
for exon 3 skipping. This region is also required for RNA export (Fig. 3) and therefore may 
contain either the RNA binding or multimerization domain. Interestingly, the deletion of the 
highly basic C-terminus (aa 144-165) which contains a proposed NLS of Rev (13) was 
deleterious to RNA export activity, but did not adversely affect alternative splicing. 
However, it is likely that the small size of the protein permitted passive diffusion into the 
nucleus. Deletion of the NES of Rev (aa 32-55) did not adversely affect alternative splicing. 
This indicates Rev-mediated RNA export is independent of alternative splicing, although 
both functions require RNA binding. Taken together, these results validate the currendy 
proposed model of EIAV alternative spUcing and more clearly define the importance of 
alternative splicing in terms of EIAV replication. 
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DISCUSSION 
Here we demonstxate tiiat, in addition to the nuclear export signal (NES), two regions 
(aa 75-127 and 145-165) of equine infectious anemia virus (EIAV) Rev are necessary for 
biological activity. In addition, aa 75-127 are required for Rev to mediate exon 3 alternative 
splicing. The majority of the deletion mutants exhibited reduced activity in vitro, indicating 
that EIAV Rev is highly sensitive to deletion mutagenesis. Only one region (aa 131-144) 
could be deleted and still maintain wild-type levels of fimction. 
One of the two areas of the protein especially sensitive to deletions (aa 145-165) has 
recendy been proposed to contain the nuclear localization signal of Rev (13). Consistent with 
that finding, deletion mutants in this region were non-functional. Surprisingly however, 
deletion of this highly basic, C-terminus of the protein, did not inhibit Rev mediated 
alternative splicing. It is likely that the small size of the mutant (-16 kDa) allowed it to 
passively diffuse into the nucleus and stUl promote exon 3 skipping. Further experiments wiU 
be necessary to confirm this hypothesis. 
Consideration of the mechanism by which EIAV Rev-mediates alternative splicing 
provides further insights into the possible function of aa 75-127. Exon 3 skipping results 
from a disruption of SR protein-ESE interactions when Rev binds a RRE in exon 3. Given 
that alternative splicing results from RRE binding and that mutants deleted in aa 75-127 are 
deficient in this function, it is likely that the RNA binding and multimerization domains are 
localized within this region of the protein. Further in vitro studies to identify the RNA 
binding domain of Rev wiU more clearly delineate the mechanisms of Rev-mediated RNA 
export and alternative splicing. However, given the broad, deleterious effects of our deletion 
analysis, more sensitive analysis, such as site-directed mutagenesis, may be necessary to 
define specific amino acids requirements of Rev function. 
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Figure 1. Splicing patterns of EIAV. Structural proteins (Gag, Env) and viral enzymes (Pol) 
are translated from the unspliced and singly-spliced mRNAs. Both Tat and Rev are encoded 
on the triply spliced, four exon mRNA. In the presence of Rev a new multiply-spliced 
mRNA appears in which exon 3 is skipped. This mRNA codes for Tat alone. The two exon 
mRNA codes for Ttm, a protein of unknown function. 
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Figure 2. (A) Deletion mutants of EIAV Rev for functional analysis. (B) Expression of 
deletion mutants. 1x10^ 293 cells were transfected with 5 ng of mutant plasmid. Two days 
posttransfection, cells were harvested and a Western blot performed. Rev mutants were 
detected using anti-EIAV polyclonal horse sera. 
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Figure 3. In vitro activity of Rev deletion mutants. (A) Transactivation of Rev reporter 
plasmid ERRE-AU by deletion mutants. ERRE-AU contains the CAT gene and an EIAV RRE 
flanked by HTV-l splice sites. Transfections were made into 293 cells and normalized by 
beta-galactosidase activity from co-transfected pCHl 10. Rev activity is measured as a 
production of CAT. Mutants are transfected in triplicate per experiment and results are from 
three experiments, standard error of the mean is shown. (B) Complementation of a Rev-
defective provirus by deletion mutants as measured by cell-supernatant reverse transcriptase 
(RT) activity. 1 x 10^ cells of Cf2Th/51 cells were transfected with 2 |ig of each mutant 
plasmid. Three days posttransfection, 10 |il of supematant was assayed for RT activity using 
[32p]TTp. RX activity was quantified by phosphoimager and the standard error of the mean is 
shown. 
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Figure 4. Alternative splicing in cells fra«^-complemented with Rev deletion nautants. 
Cf2Th/51 ceUs, containing a Rev-defective provirus, were transfected with Rev deletion 
mutatnts. Total RNA was isolated and [^"P]end-labeled RT-PCR performed using primers 
within exon two and four (see Fig. 1). DNA was extracted and separated through a 
denaturing polyacrylamide gel. The gel was dried and bands were quantified using a 
phosphorimager and the percentage of alternatively spliced message is shown. Cf2Th/l 12 
cells, a positive control cell line, contain a Rev-competent provirus. 
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CHAPTER 6. GENERAL CONCLUSION 
The complex retroviruses are defined not only by a complicated genome, but also by 
a pattern of gene expression dependent upon the action of viral regulatory proteins. The use 
of regulatory proteins creates a mechanism through which variation can modulate virus 
replication and provides a potential factor of pathogenicity. EIAV is unique both as a 
lentivirus and as a complex retrovirus which makes the virus an excellent tool for 
comparative studies. EIAV is one of the simplest complex retroviruses. Whereas HIV-1 has a 
9.7 kb genome and expresses more than 20 mRNAs with nine gene products, the EIAV 
genome is a modest 8.3 kb, has five mRNAs, and seven gene products. Lentiviruses are 
typically characterized as causing slow, chronic diseases which may take years to progress. 
EIAV however, can induce a rapid, variable disease course almost immediately upon 
infection of a horse. These are just some of the factors make EIAV an appropriate model for 
analyzing virus persistence and pathogenesis. 
Variation in ELVV Rev Correlates with Disease 
Sequence analysis of EIAV cDNAs from both in vivo and in vitro contexts indicated 
the second exon of rev contains a hypervariable region. Sequence variation in retrovimses is 
attributed to errors in nucleotide incorporation by reverse transcriptase (5, 7, 9, 11). These 
errors are generally randomized throughout the genome and then selected during virus 
replication. We found the variation in Rev to be localized to two primary regions- the 
activation domain and a stretch of amino acids bordered by QERL repeats (Chapter 2, Fig. 
2). It is possible that immune selection may account for some of the variation in Rev since 
the major rev exon (exon 4) overlaps with the ORF of gp45, the transmembrane protein of 
the virion. While our results do not rule out a role for immune selection of certain variant 
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genotypes, they argue strongly that the effect of variation in this region on Rev fiinction must 
also be considered as a plausible selective force in vivo. Further support for the role of Rev 
variation in EIAV persistence is found in the analysis of Rev variation during successive 
stages of clinical disease. 
Alterations in patterns of clinical disease during an infection result from changes in 
either the host immune response and/or changes in virus replication. Prior to these smdies, 
we reported that a heterogeneous mixture of Rev genotypes was present in the first febrile 
cycle of a horse acutely infected with EIAV (1). Functional analysis of these genotypes 
indicated the presence of both Rev-competent and Rev-defective phenotypes. Variation 
which restricts expression of virus structural genes may contribute to EIAV evasion of the 
host immune response during periods of clinical quiescence. Studies with HTV-l have 
suggested that variation in Rev phenotype may contribute to the replication potential of the 
virus, and hence viral pathogenesis (6). Indeed, in our in vivo studies of rev variation, we 
observed that highly acdve Rev-phenotypes predominated during periods of clinical disease 
and less active Rev phenotypes predominated during the acute and subclinical stages of 
disease. Restricted expression of viral structural genes is a common strategy of persistent 
viruses (10). Therefore, less active Rev phenotypes may be important for evasion of an active 
host immune response during periods of long-term persistence. Findings from this work 
provide strong evidence that variation in Rev is an important factor in both EIAV persistence 
and pathogenicity. 
Identification of tlie EIAV RREs 
In other lentiviruses, fran^-activation of the Rev/Rex RNA export pathway occurs 
through an interaction with a single RRE (reviewed in 3). For the majority of lentiviruses the 
RRE is located near the surface-transmembrane envelop region; two exceptions are FTV and 
123 
HTLV-1, for which the RREs have been mapped near the 3' end of the genome (3, 12, 13). 
The studies in Chapter 2 confirm previous reports that EIAV Rev is unique among other 
lentiviruses in that it trans-activates through two discrete regions in the viral RNA (2, 8). The 
studies in Chapter 4 further mapped the 5' element to a 57 nt region within the first rev exon. 
This is the most 5' RRE mapped among lentiviruses. However, similar to ERRE-1, the 
reporter construct containing the 57 nt ESE region showed significantly reduced activity as 
compared to the ERRE-AU reporter construct containing a larger portion of the env gene. The 
second RRE element has not been more specifically identified, nor is it clear that such an 
element can function independently of the 5' RRE to mediate export of viral pre-mRNAs. 
Furthermore, the results demonstrated the combined activities of two reporter plasmids 
containing the individual RREs was only 69% of the activity of the reporter plasmid 
containing both elements in the in vivo context. This suggests that a synergistic interaction 
between both cw-acting regions is required for optimal export activity. Additional studies 
will be necessary to fully understand the biological and evolutionary significance of the two 
RRE-containing EIAV Rev-mediated export pathway. 
Interestingly, the presence of both RREs significantly enhanced the differences in 
biological activity observed among the Rev variants in the studies of Chapter 2. The basis for 
this synergism is not clear. The sequence of ERRE-1 overlaps the Rev exon 3 sequences 
present in the variant cDNAs and it is possible that the Rev expression plasmids contain a 
cw-acting element capable of binding to Rev. Therefore, the variant expression plasmids 
provided m-trans may transcribe RNAs which compete with the reporter plasmids for Rev 
binding, thereby suppressing the full expression of CAT. If the ERRE sub-elements differed 
in their affinity for Rev binding, it could also explain the finding that the sum of the activities 
of the individual reporter plasmids was only 69% of the activity of the reporter containing 
both elements. Computer modeling predicts different RNA secondary structures for the RRE 
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present in Rev cDNAs versus the RREs in the reporter plasmids and it is not obvious that the 
variant cDNAs could act as a competitive inhibitor of ERRE-1. Clearly, more detailed 
biochemical analysis of the EIAV cw-acting sequences is needed. 
EIAV Rev-mediated alternative splicing 
In facilitating the export of incompletely spUced mRNAs, HTV-l Rev and HTLV-1 
Rex inhibit the expression of both Tat and Rev specific mRNAs. The EIAV Rev export 
pathway is unique from HTV-l and HTLV-1 in that EIAV Rev specifically down-regulates 
its own production, independent of Tat, by promoting exon 3 skipping of the bicistronic 
mRNA (4, 8). This mechanism allows for continuous production of Tat while Rev synthesis 
is limited. The analysis of the multiply spliced RNAs from both Rev-defective and Rev-
competent cell lines in Chapter 2 confirms that alternative splicing is a Rev-dependent 
phenomenon. The prior model of EIAV Rev dependent altemative splicing proposed that 
binding of Rev to the RRE overlapping exon 3 interferes with SR protein-RNA or SR 
protein-snRNP interactions to promote exon 3 skipping (4). Consistent with this model, 
amino acid variation which altered the RNA export function of the protein did not alter the 
altemative splicing, and a variant deficient for RNA export retained the ability to promote 
skipping of the third exon. These results suggested the two functions most likely occupy 
separate domains in the protein, although both functions may require RRE binding. The 
multifunctional nature of EIAV Rev highlights its importance in terms of regulation of virus 
gene expression and replication. As such, genetic and biological variation in Rev may have 
added significance in vivo. 
The studies in Chapter 4 demonstrate that the purine rich sequence within exon 3 of 
equine infectious anemia virus (EIAV) is both an exon splicing enhancer (ESE) and a 
functional Rev responsive element (RRE). The use of an ESE as an RRE is unprecedented 
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among complex retroviruses. A prior study demonstrated that the SR protein ASF/SF2 cross­
links in vitro with exon 3 and suggested that the purine rich sequence was an ESE (4). 
Consistent with this previous data, we demonstrated that the purine rich sequence is required 
for exon 3 recognition in splicing reactions in vitro. Taken together, these data suggest 
ASF/SF2 is the SR protein required for efficient splicing of exon 3. The ability of a 57 nt 
sequence containing the ESE to interact in vitro with GST-Rev and act as a functional RRE 
in a heterologous nuclear export assay system demonstrates this region contains a functional 
BIRE. The mutation studies of GAA nucleotide repeats in the ESE confirmed both exon 3 
splicing and Rev-mediated RNA export have similar c/5-acting RNA requirements. 
Therefore, we propose that Rev-mediated nuclear export requires binding at or near the ESE 
and results in skipping of exon 3 through an inhibition of ASF/SF2-ESE interactions required 
for recognition of exon 3 by the host cell splicing machinery. 
Future studies 
Together, these studies comprise a comprehensive genetic and molecular 
characterization of EIAV Rev, providing insights into the pathogenesis of the virus and the 
molecular mechanisms of virus replication. Many questions remain however, both to confirm 
some of the data presented here and to complete the functional studies of Rev. In Chapter 2 
we identified two independent RREs of EIAV. The 5' RRE was further delineated in Chapter 
4 to a 57 nt region, however this RRE had severely reduced activity in comparison to the 
ERRE-AU reporter. This suggests that the 3' RRE is necessary for full function. Since that 
publication, little characterization of the 3' RRE has been done. Further studies mapping the 
exact location of this RRE are required to fuUy delineate the role of the 3' RRE and its 
importance in the EIAV Rev export pathway. 
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The exhaustive analysis of pony 524 described in Chapter 3 provides strong evidence 
that variation in Rev contributes to EIAV persistence and pathogenesis. One weakness of this 
work is that the analysis was performed in a single animal undergoing a particular form of 
disease. EIAV can also induce an acute disease which results in death within several weeks, 
or inapparently infected horses. I would recommend examining rev variation in these other 
tj-pes of experimentally infected animals as a mechanism to confirm our findings in pony 524 
and further define the significance of Rev variation in EIAV pathogenesis. 
We clearly delineated the mechanism of Rev-mediated exon 3 skipping in Chapter 4. 
Since SR proteins interact at the RRE, they potentially can inhibit Rev function. A previous 
study in our laboratory, mentioned in the discussion of Chapter 3, demonstrated a down-
regulation of Rev activity in activated macrophages. This suggests that such an inhibition 
may result from an upregulation of SR proteins during activation of macrophages. However, 
little is known about the phenotype of SR proteins in macrophages. Therefore I reconmiend 
further studies to determine the role of SR proteins in EIAV replication. These studies should 
begin by determining if excess SR proteins can inhibit EIAV replication. If this occurs, then 
it would be important to confirm the inhibition results from a down-regulation of Rev 
activity. Finally, the phenotype of SR proteins should be studied in quiescent and activated 
macrophages to determine what changes in SR proteins are associated with activation state. 
The functional mapping of Rev has just begun. The deletion mutants described in 
Chapter 5 are a good tool to further identify the domains required for Rev activity. Indeed, 
the studies described in Chapter 4 would suggest that the altemative splicing domain mapped 
in Chapter 5 is actually the RNA binding domain of Rev. This can be readily determined 
using the deletion mutants in RNA gel mobility shift assays. However, it would appear that 
either smaller deletions or site-directed mutagenesis will be necessary to more finely identify 
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any domain. RNA binding studies should also delineate the multimerization domain. 
Following confirmation of the nuclear localization signal. Rev will be completely mapped. 
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